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Abstract
Immune cells employ a diverse array of metabolic programs upon stimulation that have far-reaching
consequences outside of energy production. Activated T cells require glycolysis to generate the biosynthetic
intermediates for proliferation and to enhance effector functions. Due to the disorganized vasculature of solid
tumors and the highly glycolytic nature of tumor cells, T cells must compete for glucose with tumor cells in a
nutrient-depleted environment. We hypothesized that cells that traffic to inflamed, nutrient-limiting
environments in the periphery (effector memory T cells, TEM) may have enhanced abilities to adapt to
nutrient limitation compared to cells that largely reside in nutrient-rich lymphoid organs (naïve and central
memory T cells, TN and TCM respectively). We demonstrate that TN and TCM rely on fatty acid
metabolism to survive and proliferate when glucose is limiting, whereas TEM do not. Furthermore, we find
the reliance on fatty acid metabolism in limiting glucose by TN and TCM cells regulates IFN-γ production.
Thus the first section of my thesis identifies a novel regulatory interaction between fatty acid synthesis and
effector function. Other byproducts of metabolic pathways can also affect immune cell function. Recent work
has suggested that reactive oxygen species are released following activation, which promote proliferative
signals in T cells such as IL-2 production. The second section of my thesis investigates how T cells increase
reactive oxygen species (ROS) production following activation. Using transmission electron microscopy we
observe dramatic alterations to mitochondrial morphology following T cell activation. Mitochondria
significantly increase in size and their cristae lose parallel patterning during the first 48 hours of T cell
activation. Mitochondrial swelling and cristae disturbance are glucose and mTORC1 dependent, and highly
reversible. Interestingly, we find that mitochondrial swelling does not correlate to oxidative phosphorylation
rate, but strongly correlates to ROS production. We speculate that these mitochondrial changes are required to
create the ROS necessary for subsequent IL-2 production and T cell proliferation. Together these data
demonstrate novel relationships between cellular metabolism and cytokine production in CD4 T cells. By
identifying how metabolites specifically affect immune function, we hope to exploit these discoveries in future
cancer immunotherapies.
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ABSTRACT 
 
UNDERSTANDING METABOLIC ADAPTATION OF T CELLS DURING ACTIVATION AND 
NUTRIENT LIMITATION 
Christopher M. Ecker 
James L. Riley 
 
Immune cells employ a diverse array of metabolic programs upon stimulation 
that have far-reaching consequences outside of energy production. Activated T cells 
require glycolysis to generate the biosynthetic intermediates for proliferation and to 
enhance effector functions. Due to the disorganized vasculature of solid tumors and the 
highly glycolytic nature of tumor cells, T cells must compete for glucose with tumor cells 
in a nutrient-depleted environment.  We hypothesized that cells that traffic to inflamed, 
nutrient-limiting environments in the periphery (effector memory T cells, TEM) may have 
enhanced abilities to adapt to nutrient limitation compared to cells that largely reside in 
nutrient-rich lymphoid organs (naïve and central memory T cells, TN and TCM 
respectively).  We demonstrate that TN and TCM rely on fatty acid metabolism to survive 
and proliferate when glucose is limiting, whereas TEM do not.  Furthermore, we find the 
reliance on fatty acid metabolism in limiting glucose by TN and TCM cells regulates IFN-γ 
production.  Thus the first section of my thesis identifies a novel regulatory interaction 
between fatty acid synthesis and effector function.  Other byproducts of metabolic 
pathways can also affect immune cell function.  Recent work has suggested that reactive 
oxygen species are released following activation, which promote proliferative signals in 
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T cells such as IL-2 production.  The second section of my thesis investigates how T cells 
increase reactive oxygen species (ROS) production following activation.   Using 
transmission electron microscopy we observe dramatic alterations to mitochondrial 
morphology following T cell activation.  Mitochondria significantly increase in size and 
their cristae lose parallel patterning during the first 48 hours of T cell activation.  
Mitochondrial swelling and cristae disturbance are glucose and mTORC1 dependent, 
and highly reversible. Interestingly, we find that mitochondrial swelling does not 
correlate to oxidative phosphorylation rate, but strongly correlates to ROS production.  
We speculate that these mitochondrial changes are required to create the ROS 
necessary for subsequent IL-2 production and T cell proliferation.   Together these data 
demonstrate novel relationships between cellular metabolism and cytokine production 
in CD4 T cells.  By identifying how metabolites specifically affect immune function, we 
hope to exploit these discoveries in future cancer immunotherapies. 
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Chapter 1- Connecting T cell metabolism to effector function 
 
Upon antigen encounter in T cells or toll like receptor signaling in macrophages 
and dendritic cells, glycolysis even in the presence of oxygen is dramatically upregulated 
in a phenomenon known as the “Warburg effect” (Everts et al., 2014; Frauwirth et al., 
2002; Galván-Peña and O'Neill, 2014).  Warburg metabolism was first described in 
cancer cells, in which proliferating cells rely on high rates of aerobic glycolysis (Vander 
Heiden et al., 2009).  Much of the early focus on cancer metabolism examined why 
highly proliferating cells rely on aerobic glycolysis, as it is far less efficient than oxidative 
phosphorylation for production of ATP.  A number of hypotheses were proposed to 
explain why proliferating malignant cells largely utilize aerobic glycolysis: 1) cancer cells 
are forced to use glycolysis because of mitochondrial damage from transformational 
mutations; 2) the rate of aerobic glycolysis occurs 10-100 fold faster than oxidative 
phosphorylation; 3) increased glucose uptake allows tumor cells to outcompete healthy 
cells in nutrient limiting environments; 4) aerobic glycolysis generates biosynthetic 
intermediates that can be used to produce the necessary building blocks for 
proliferation; and 5) aerobic glycolysis confers chromatin remodeling or other metabolic 
signals that drive proliferation (Liberti and Locasale, 2016; Locasale and Cantley, 2011; 
Vander Heiden et al., 2009).  All of these proposals may not be mutually exclusive, and 
may differ in their importance between proliferating cancer cells and stimulated 
immune cells.   
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From a bioenergetic standpoint, it is unclear whether ATP demand ever reaches 
limiting values during proliferation and there are some models that propose ATP 
requirements for division are less than those of normal cellular maintenance (Pfeiffer et 
al., 2001).  The most well supported view is that proliferating cells rely on aerobic 
glycolysis to generate the cellular building blocks necessary for proliferation.  For 
instance, glycolytic intermediates can produce nucleotides, fatty acids, and amino acids 
required for creating a new cell (Vander Heiden et al., 2009).  In addition, altered 
concentrations of metabolites can promote proliferation though epigenetic 
modifications and reactive oxygen species (ROS) signaling (Kong and Chandel, 2018; 
Reid et al., 2017).  Many of the original hypotheses focused on why aerobic glycolysis 
was necessary for rapid cellular proliferation, and were specifically applied in the 
context of T cell metabolism during activation (Fig 1-1).  However, these ideas do not 
sufficiently explain why macrophages and dendritic cells increase aerobic glycolysis 
upon TLR stimulation since these cells do not proliferate (Galván-Peña and O'Neill, 
2014).  It was this observation combined with early work by Chang et al. that proposed a 
bold new hypothesis, that aerobic glycolysis is necessary for immune cells to initiate 
effector programs (Chang et al., 2013).   
The last decade brought enormous interest to studying the metabolism of 
immune cells.  Two key aspects of immunometabolism were essential for the field’s 
expansion: 1) the requirement and magnitude of metabolic changes immune cells 
undergo upon stimulation, and 2) the ability to tie those metabolic changes to 
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functional consequences. T cells have been at the forefront of immunometabolism 
because they can be easily isolated, expanded, transduced, adoptively transferred, and 
exhibit dramatically different metabolic states upon activation.  In addition, lessons 
learned from T cell metabolism have been applied and translated to other immune cell 
types.   
Historically, glycolysis has been the most studied metabolic pathway in T cells 
because glucose is the most consumed metabolite by activated T cells.  T cell activation 
increases glycolysis largely by driving surface expression of the glucose transporter in T 
cells, Glut1, through Akt signaling (Frauwirth et al., 2002; Jacobs et al., 2008).  While T 
cells predominantly express Glut1, T cells also express transcript for other glucose 
transporters including Glut 3, 6, and 8 (most of which do not increase mRNA expression 
following stimulation).  Co-stimulation receptor expression is required for maximal Akt 
activation and Glut1 surface expression and subsequent glycolysis (Jacobs et al., 2008; 
Macintyre et al., 2014; Siska et al., 2016).  Glut1 is expressed in effector T cell subsets 
such as CD8+ T cells and CD4+ Th1, Th2, and Th17 cells, and all of these cells strongly 
engage glycolysis following activation to proliferate (Macintyre et al., 2014).   Glycolytic 
intermediates contribute to the numerous biosynthetic and energy generating pathways 
(the pentose phosphate pathway and serine biosynthesis pathway to generate 
nucleotides, to generate acetyl-CoA and TCA cycle intermediates critical for epigenetic 
modifications and energy, and for fatty acid synthesis from glucose-derived citrate).  T 
cell specific deletion of Glut1 inhibits effector T cell proliferation and survival upon 
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stimulation in vivo (Macintyre et al., 2014).  Interestingly, T regulatory cells appear in 
higher numbers in those mice potentially due to increased niche space, and retain 
suppressive function in in vitro (Michalek et al., 2011).  However recent work has 
suggested that glycolysis is still important in T regulatory cells for migration into 
inflammatory environments and for in vivo and in vitro proliferation (Kishore et al., 
2017; Procaccini et al., 2016).   Furthermore limiting glucose availability specifically 
inhibits effector function by regulating IFN-γ production by at least two independent 
mechanisms: 1) available glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a 
glycolytic enzyme, binds to the 3’ untranslated region of IFN-γ and inhibits translation, 
and 2) limiting glucose lowers the cellular pool of acetyl-CoA which subsequently lowers 
histone acetylation of the IFN-γ promoter (which may be highly sensitive to changes in 
acetylation  (Chang et al., 2013; Peng et al., 2016).  These mechanisms are further 
discussed in chapter 3.  Interestingly, inhibiting glycolytic rate of proliferating T cells 
prevents terminal differentiation and promotes memory development of adoptively 
transferred T cells (Sukumar et al., 2013). The authors further demonstrated that 
enforcing elevated glycolysis by overexpressing the glycolytic enzyme, phosphoglycerate 
mutase-1, promoted effector function at the cost of memory differentiation. Thus 
glucose works to fulfill the biosynthetic, proliferative, and functional needs of activated 
T cells and regulates memory development. 
Glutamine is also incredibly essential to effector T cell activation and survival.  
Upon activation T cells increase mRNA and protein expression of several glutamine 
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transporters, including SLC38A1 and SLC38A2 (Bhutia and Ganapathy, 2016; Carr et al., 
2010).  Glutamine can also be routed into diverse fates critical for proliferating cells.  
Besides from being used for protein synthesis directly, glutamine can be metabolized 
into glutamate and subsequently into TCA cycle intermediates, or used for fatty acid 
synthesis through reductive glutaminolysis, can produce several other amino acids 
(alanine, aspartate, etc.), and is a critical nitrogen donor for purine and pyrimidine 
nucleotide synthesis (Cluntun et al., 2017; DeBerardinis and Cheng, 2010).  Utilization of 
glutamate or cell-permeable α-ketoglutarate is not sufficient to rescue effector T cell 
proliferation in glutamine-deficient media (Carr et al., 2010).  These data suggest that 
glutamine’s roles outside of the mitochondria are critical for activated effector T cells.  
Interestingly, limiting glutamine availability also promotes T regulatory cell polarization 
of naïve CD4 T cells, but is reversed by adding cell-permeable α-ketoglutarate, a TCA 
cycle intermediate and glutamine derivative (Klysz et al., 2015).    Interestingly, 
glutamine utilization for oxidative phosphorylation and amino acid synthesis pathways 
may be increased during glucose limitation in T cells to compensate for losses in energy 
production (Blagih et al., 2015).     
Other amino acids at least by magnitude are consumed less than glutamine, but 
nevertheless serve critical roles in T cell metabolism for proliferation and function.  
While the glycolytic intermediate 3-phosphoglycerate (3-PG) can be converted to serine, 
extracellular serine is required for optimal T cell expansion even when glucose 
availability is high (Ma et al., 2017b).  Serine can be made into glycine and used for de 
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novo purine synthesis through one carbon metabolism.  Ma et al. further demonstrated 
that dietary restriction of serine impairs T cell responses in a mouse model of Listeria 
monocytogenes infection.  In addition, T cells deficient in the neutral amino acid 
transporter Slc7a5 (most commonly transports leucine), were unable to proliferate or 
differentiate into effector cells in response to antigen (Sinclair et al., 2013).  
Interestingly, these T cells produced equal amounts of IL-2 as wild-type cells but were 
compromised in glucose uptake and IFN-γ production.  Limiting extracellular arginine 
impairs T cell glycolysis upon activation and subsequent proliferation (Fletcher et al., 
2015).  Furthermore, the absence of extracellular arginine in activated T cells impairs 
expression of CD3ε and CD3ζ and production of many cytokines such as IFN-γ, IL-5, IL-
10, but not others like IL-2 (Zea et al., 2004).  Tryptophan metabolites in the kynurenine 
pathway can be produced by the enzyme indoleamine 2,3-dioxygenase (IDO), and are 
expressed by many antigen presenting cells and tumor cells in the tumor 
microenvironment (Schafer et al., 2016).  High expression of IDO can cause local 
depletion of tryptophan to regulate T cell proliferation, and the kynurenine metabolites 
can independently induce T cell apoptosis (Fallarino et al., 2002; Platten et al., 2012).  
Furthermore, amino acid recycling in lymphocytes is required for effective immunity in 
humans.  Patients with loss-of-function mutations in tripeptidyl peptidase II are unable 
to maintain intracellular amino acid levels, exhibit impaired IFN-γ and IL-1β production, 
and prone to recurrent infections and autoimmunity (Lu et al., 2014).  
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 Fatty acids perform numerous functions for the cell.  They are essential 
components of cell membranes, act as important secondary signaling molecules during 
T cell activation, can post-translationally modify important proteins, and act as an 
energy resource.    T cells often acquire fatty acids from their environment through fatty 
acid transporters, but can also generate their own by de novo fatty acid synthesis.  In 
CD4+ T cells, inhibition of a critical enzyme for fatty acid synthesis, acetyl-CoA 
carboxylase 1 (ACC1) promoted the polarization of T regulatory cells at the cost of Th1, 
Th2, and Th17 development  (Berod et al., 2014).  CD8+ T cells also require ACC1 for 
survival and proliferative responses during homeostasis and infection  (Lee et al., 
2014a).  Both Berod et al. and Lee et al. demonstrated that addition of extracellular fatty 
acids rescues many of these alterations in polarization or defects in proliferation.  These 
data suggest that CD8+ T cells can overcome defects in fatty acid synthesis by 
exogenous uptake of fatty acids, however for CD4+ T cells the source of fatty acids and 
the oxidation or synthesis of those fatty acids may impact polarization.  Proliferating T 
regulatory cells require both fatty acid oxidation and glycolysis for proliferation and 
function  (Procaccini et al., 2016).  Promoting fatty acid metabolism by overexpressing 
carnitine palmitoyl transferase 1a (CPT1a) promotes T cell survival and memory 
development in vivo (van der Windt et al., 2012).  Interestingly, driving fatty acid 
metabolism often has similar affects to glucose limitation by promoting memory and 
regulatory T cell development, and limiting effector function.  This relationship between 
glucose limitation and fatty acid metabolism is further explored in Chapter 3. 
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Glucose, amino acid, and fatty acid effects on T cell polarization and memory 
development can partially be explained by the mammalian target of rapamycin (mTOR) 
activity.  mTOR acts in two complexes, mTORC1 and mTORC2, and integrates nutrient 
availability, growth factors and energy levels (as well as  other factors) to regulate 
metabolism and proliferation (Laplante and Sabatini, 2012; Sabatini, 2017).  Glucose and 
many amino acids are required for mTORC1 activation following effector T cell 
activation.  In turn, mTOR activity can regulate numerous transcription factors involved 
in glycolysis, fatty acid oxidation, and fatty acid synthesis like hypoxia inducible factor 1α 
(HIF-1α), myc, peroxisome proliferator-activated receptor alpha, peroxisome 
proliferator-activated receptor gamma, and the sterol regulatory element-binding 
protein family of transcription factors (Waickman and Powell, 2012; Zeng and Chi, 
2017).  Inhibition of mTORC1 in T cells promotes memory development during viral 
infection (Araki et al., 2009; Bengsch et al., 2016).  Inversely, loss of tuberous sclerosis 1, 
a negative regulator of mTOR signaling, promotes effector function at the cost of 
memory development in a mouse model of Listeria monocytogenes infection (Shrestha 
et al., 2014).  This patterning of mTOR activity is nearly identical to the observations that 
promoting glycolysis drives effector differentiation, while inhibiting glycolysis promotes 
memory development (Sukumar et al., 2013).   T regulatory cell polarization and lineage 
stability require phosphatase and tensin homolog (PTEN), a negative regulator of Akt 
and mTORC1 activity, to maintain metabolic balance between glycolysis and 
mitochondrial metabolism (Shrestha et al., 2015) .  HIF-1α is stabilized downstream of 
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mTORC1, promotes glycolysis and effector T cell function and polarization (Dang et al., 
2011; Doedens et al., 2013).  Furthermore mice with deficiency in HIF-1α are strikingly 
defective in Th17 polarization, while simultaneously promoting T regulatory cell 
polarization (Dang et al., 2011; Hsiao et al., 2015).   Thus the proliferation, polarization, 
and function of effector, memory, and T regulatory cells are strikingly dependent on a 
careful balance of nutrient availability and mTOR activity. 
However many of the observations listed above cannot be fully explained by 
simple mTOR activity. For example, metabolites and metabolic enzymes affect specific 
cytokine production by immune cells often in surprising and novel ways.  None of our 
current understanding of immunometabolism could have predicted the glycolytic 
enzyme, GAPDH’s ability to bind specifically to IFN-γ mRNA and prevent translation 
(Chang et al., 2013).    Multiple metabolic intermediates and cofactors (i.e. α-
ketoglutarate, acetyl-CoA, S-adensoylmethionine, and nicotinamide adenine 
dinucleotide) regulate, or are essential for, the activity of many epigenetic modifying 
enzymes (Etchegaray and Mostoslavsky, 2016; Wellen et al., 2009).  The laboratory of 
Luke O’Neill has publically presented unpublished work that certain TCA intermediates 
like succinate may directly regulate the production of effector cytokines.  Mitochondria-
generated ROS are not just metabolic byproducts that cause damage to cellular 
structures, but can relay important proliferative signals in tumor cells and in T cells.   
ROS regulate the ERK MAPK, HIF-1α, and JNK signaling pathways in tumor cells, and are 
instrumental for IL-2 signaling and subsequent T cell proliferation (Gauron et al., 2013; 
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Kong and Chandel, 2018; Sena et al., 2013; Weinberg et al., 2010).  In addition to their 
role in energy production, mitochondria appear to serve to produce many important 
metabolites that can regulate cellular signaling in numerous ways.  These roles of the 
mitochondria in T cell activation are further explored in Chapter 4. 
Metabolism is a highly regulated network of pathways simultaneously regulating 
cell processes well beyond energy production.  Recent work has discovered surprising 
regulatory interactions between metabolites and molecules important for immune 
function.   Future work will need to expand these concepts into in vivo tissue biology 
and mechanistic understanding of how these regulatory interactions operate with 
controlled specificity. 
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Figure 1-1:  Why do cells engage Warburg metabolism? 
For many years researchers questioned why tumor cells relied so heavily on ATP-
inefficient Warburg metabolism instead of oxidative phosphorylation.  Most of the 
evidence has supported three main concepts.  1)  Tumor cells may gain a proliferative 
advantage by drastically increasing glucose uptake and consumption, and thus starving 
nearby cells of the nutrients needed to support proliferation.  2) Glycolytic 
intermediates also help to generate important cellular building blocks needed for 
proliferation.  3) Glycolysis promotes cellular signaling pathways that facilitate 
proliferation through alterations of redox potential, mitochondrial ROS production, and 
chromatin remodeling.  Taken together, tumor cells rely on Warburg metabolism 
because it facilitates the signals and demands a rapidly dividing cell needs.   In recent 
years, researchers have learned that many stimulated immune cell types also rely on 
Warburg metabolism. T cells stimulated through their TCR and co-stimulatory domains, 
or some subsets of macrophages and dendritic cells stimulated through TLRs, rapidly 
upregulate Warburg metabolism.  However many of these immune cell populations 
utilize Warburg metabolism without subsequent proliferation. These ideas sparked the 
hypothesis that stimulated immune cells use Warburg metabolism to enhance immune 
function. 
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Figure 1-2: Metabolic pathways generate intermediates important for biosynthesis in 
T cells. 
During activation T cells rapidly upregulate glycolysis for energy and to generate the 
building blocks of a new cells.  Glycolysis produces ATP and facilitates de novo 
nucleotide production through the pentose phosphate and serine biosynthesis pathway.  
While most pyruvate is shuttled out of the cell as lactate in activated T cells, some 
pyruvate can be shuttled into the mitochondria for the TCA cycle.  During activation T 
cells also upregulate oxidative phosphorylation by increasing fatty acid oxidation, 
glutamine uptake.  T cells can further utilize fatty acid synthesis to generate de novo 
fatty acids.  Together glycolysis, oxidative phosphorylation, glutaminolysis, fatty acid 
oxidation and synthesis represent the most well studied metabolic pathways in T cells. 
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Chapter 2- The perils of using adoptive T cell approaches to study 
tumor/T cell metabolic competition 
 
Parts of this chapter are currently under review in: 
Christopher Ecker, James Riley.  Translating in vitro T cell metabolic findings to in vivo 
tumor models of nutrient competition.  Cell Metabolism.  Submitted. 
 
Exciting new technologies and conceptual advancements have re-energized the 
study of the metabolic competition between tumors and the adaptive immune system 
(Chang et al., 2015b; Ho et al., 2015a; Sugiura and Rathmell, 2018).  Despite these 
advancements, there remains little discussion in the literature on how investigators 
should model nutrient depletion in the tumor microenvironment when studying 
immune cell/tumor cell metabolic interactions and competition.  How can we more 
accurately distinguish and dissociate nutrient deprivation’s effects on immune cells from 
other immunosuppressive components of the tumor microenvironment in vivo?  Are T 
cells engineered with altered metabolic programming specifically overcoming a nutrient 
limitation or are they simply better tumor-specific T cells that function better in all 
nutrient environments?  This essay will lay out some of the critical issues facing the field 
and hopefully spur the development of improved approaches for testing new immune 
therapies.  We believe that greater mechanistic understanding of immunometabolism 
will fully harness the clinical potential of immune therapies. 
Challenges T cells face in the solid tumor microenvironment 
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In vivo, tumors alter the abundance of dozens of metabolites in the interstitial 
fluid relative to healthy tissue (Kamphorst et al., 2015; Pavlova and Thompson, 2016).  
Most commonly solid tumor environments have been reported to be deprived of 
oxygen, glucose, glutamine, and arginine and highly acidic (Fig 2-1 A).  Different tumors 
and even separate regions of the same tumor can host diverse nutrient environments 
and can experience intermittent blood flow and nutrient supply (DeBerardinis and 
Chandel, 2016; Vaupel et al., 1987).  An abundance of pro-angiogenic factors (like 
vascular endothelial growth factor-A) promote disturbed vasculature characterized by 
large and leaky vessels, erratic branching, and irregular and slow blood flow which 
inhibits efficient nutrient delivery (Carmeliet, 2005; Lanitis et al., 2015).  T cells require 
glucose, glutamine, and mitochondrial pathways for activation, maximal proliferation 
and/or effector function (Cham and Gajewski, 2005; Macintyre et al., 2014; Procaccini et 
al., 2016; Ron-Harel et al., 2016; Sena et al., 2013).  Aerobic glycolysis serves the 
increased biosynthetic demands of highly proliferating cells.  Glycolytic intermediates 
can produce nucleotides, lipids, and amino acids necessary for cellular proliferation in 
both T cells and cancer cells (Vander Heiden et al., 2009).  Similar reliance on aerobic 
glycolysis between proliferating cancer cells and activated T cells intensifies a 
competition for limited nutrients within the tumor microenvironment.  Competition for 
glucose also plays a clear role in limiting effective anti-tumor responses in vivo (Chang et 
al., 2015b; Ho et al., 2015a).  Aerobic glycolysis is required for maximal IFN-γ production 
by effector T cells though two independent mechanisms.  The glycolytic enzyme 
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glyceraldehyde-3-phosphate dehydrogenase (GAPDH) can inhibit translation of IFN-γ 
mRNA, while another study has demonstrated that the glycolytic enzyme, lactate 
dehydrogenase A (LDHA), promotes histone acetylation along the IFN-γ locus (Chang et 
al., 2013; Peng et al., 2016).  Although some attempts to increase nutrient availability 
have been successful, we have little understanding how to make T cells more fit in a 
nutrient limiting environment  (Chang et al., 2015b; Lanitis et al., 2015). 
Due to dysfunctional vasculture and the high glycolytic rate of many tumor cells, 
the tumor microenvrionment is often acidic because of high lactate concentrations (Fig 
2-1 B).  Both tumor and T cells rely on monocarboxylate transporters to secrete and 
uptake lactate generated from glycolysis and pyruvate.  High lactate concentrations in 
the environment prevent T cells from efficiently transporting lactate out of the cell and 
increase intracellular acidity and inhibit functionality and NFAT activity (Brand et al., 
2016; Fischer et al., 2007).   Brand et al. demonstrated that melanoma tumor cells 
engineered to have low lactate dehydrogenase A (LDHA) activity, have greater immune 
infiltration and activity than tumor cells with normal LDHA expresion.  LDHA is the 
glycolytic enzyme required for conversion of pyruvate to lactate.   Furthermore the 
administration of the proton pump inhibitor, esomeprazole, can normalize tumor pH in 
vivo and when combined with immunotherapy can promote tumor clearance 
(Calcinotto et al., 2012).  While glucose deprivation and high lactate concentrations 
inhibit anti-tumor responses, they also promote immunosuppressive T regulatory cell 
and macrophage polarization and function (Angelin et al., 2017; Colegio et al., 2014).   
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As T cells become exposed to chronic antigen in the tumor microenvironment 
they begin to terminally differentiate and become exhausted.  As exhaustion becomes 
more severe, T cells increase expression of multiple inhibitory receptors, while 
simultaneously inhibiting costimulatory receptor expression (Fig 2-1 C).  Inhibitory 
receptors can inhibit co-stimulation and phosphorylation events downstream of T cell 
receptor (TCR) activation, and prevent activation signals (Akt and mTORC1) necessary 
for increasing surface expression of the major glucose transporter, Glut-1, in T cells 
(Jacobs et al., 2008; Siska et al., 2016).  Without sufficient surface expression of Glut-1, 
the activated T cells are unable to properly upregulate glycolysis and have inhibited 
proliferation and effector function.   
Chronic antigen exposure affects metabolic pathways beyond glycolysis, by 
inhibiting mitochondrial functions (Fig 2-1 D).  Exhausted T cells in models of cancer or 
chronic virus infection often have defects in mitochondria number, size, and voltage 
potential and function (Bengsch et al., 2016; Scharping et al., 2016; Siska et al., 2017b).  
Upregulation of mitochondrial pathways (oxidative phosphorylation and one-carbon 
metabolism) are essential for proper T cell proliferation. (Chang et al., 2013; Procaccini 
et al., 2016; Ron-Harel et al., 2016; Ron-Harel et al., 2015).  In addition mitochondria 
play roles beyond producing energy and biosynthesis, though epigenetic and signaling 
roles during T cell activation (Minocherhomji et al., 2012; Sena et al., 2013).  The tumor 
microenvironment downregulates mitochondrial biosynthesis by inhibiting expression of 
PPAR-gamma coactivator 1α (PGC1α) by chronic Akt signaling (Scharping et al., 2016).  
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Furthermore, Scharping et al. demonstrated that overexpression of PGC1α in tumor-
specific T cells is able to prevent downregulation of mitochondrial mass and enhance T 
cell functionality in the tumor microenvironment.  Thus  
 Tumor infiltrating lymphocytes are exposed to large amounts of reactive oxygen 
species (ROS, Fig 2-1 E). ROS are highly chemically reactive and can damage cellular 
structures, and inhibit T cell activation.   Production of ROS drastically increases in T cells 
exposed to hypoxia and is one of the major mechanisms of immune suppression by 
myeloid derived suppressor cells (Kusmartsev et al., 2004; Tafani et al., 2016).  Myeloid 
derived suppressor cells are a heterogeneous immunosuppressive subset of cells 
overexpressed in patients and mice with cancer.   While ROS are necessary for IL-2 
production and proliferation by T cells, it remains unclear the quantities in which ROS 
will become harmful to T cells (Sena et al., 2013).  Exposure to oxidative stress by low 
doses of exogenous hydrogen peroxide are sufficient to inhibit T cell functionality and 
survival (Ligtenberg et al., 2016).   
Challenges of applying immunometabolism findings to tumor models in vivo.   
Given the metabolic challenges tumor-specific T cells face, there have been 
numerous attempts to mitigate these effects via pharmacological or genetic 
modifications to improve tumor-specific T cell therapy in vivo.  However our 
interpretation of in vivo studies has been hindered by numerous technical and biological 
challenges. 
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Distinguishing mechanism(s) of therapy 
It is incredibly difficult to distinguish whether newly designed immune 
interventions targeting the metabolic challenges of solid tumors have generated T cells 
that operate better in nutrient depleted environments or simply have made a better T 
cell (that operates better in all environments).  The key to distinguishing these 
possibilities are 1) identifying how a modification improves the anti-tumor response and 
2) understanding how individual metabolic interactions lead to distinct functional 
outcomes.  For example, enhancing mitochondrial fusion, increasing L-Arginine media 
concentrations, or inhibiting glycolytic metabolism while T cells are being expanded for 
adoptive cell therapy all enhance the therapeutic activity of the infused T cells (Buck et 
al., 2016; Geiger et al., 2016; Sukumar et al., 2013).   All of these interventions alter T 
cell metabolism, but do they enable T cells to function better in the tumor 
microenvironment?  It is challenging to envision a mechanism by which temporarily 
expanding T cells in low glucose empowers them to function better in the tumor 
microenvironment.  Rather, previous studies demonstrate that T cells expanded in low 
glucose retain a less differentiated phenotype which enables improved engraftment of 
the expanded T cells which correlates with improved tumor control (Gattinoni et al., 
2011).  Expansion in the presence of higher levels of L- arginine also results in T cells that 
are less differentiated and more reliant on oxidative phosphorylation instead of 
glycolysis  (Geiger et al., 2016).   These cells have higher intracellular concentrations of 
L-arginine, which may make them resistant to low arginine levels in the tumor 
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microenvironment.  Likewise, T cells with enhanced mitochondrial fusion are less 
differentiated in culture and exhibit greater reliance on oxidative phosphorylation (Buck 
et al., 2016).  Enhanced fusion may enhance mitochondrial function and combat 
mitophagy frequently observed during nutrient deprivation (Rambold et al., 2011).  How 
do we determine to what extent differentiation or improved fitness in the tumor 
microenvironment results in improved tumor clearance?  Future studies must work to 
better distinguish mechanisms of metabolic immune interventions to provide 
mechanistic understanding of immunometabolism (Fig 2-2 A).   
Speed of metabolic adaption and metabolite decay 
Unlike standard epigenetic or transcriptional changes that often occur over 
several hours or days, many metabolic changes occur incredibly quickly in response to 
different environments.  This may even be more pronounced in immune cells, because 
these cells readily circulate and traffic to diverse areas of the body, and thus must be 
able to adapt rapidly in diverse metabolic environments.  While researchers can observe 
cell intrinsic differences of different T cell subsets in vitro, how much information is lost 
because of isolation and prolonged in vitro expansion (Dimeloe et al., 2016a; Pan et al., 
2017; Procaccini et al., 2016; van der Windt et al., 2012)? Quantification is further 
complicated during conventional in vitro extraction techniques because of metabolite 
loss, leakage, or decay (Chen et al., 2016; Van Gulik et al., 2012; Vuckovic et al., 2011; 
Yang et al., 2017).   Thus, during commonly used isolation procedures and before any 
assay can be performed in vitro, metabolic changes are occurring (Fig 2-2 B).  Alternative 
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approaches such as utilizing isotopic tracers are highly compatible with in vivo models, 
can be easily administered, and may better recapitulate in vivo biology (Hensley et al., 
2016; Sun et al., 2017).   
Utilizing relevant cell populations in nutrient depletion studies 
Immune cells isolated for nutrient depletion studies should represent the cells 
that would traffic to sites of inflammation and nutrient depletion in the tumor 
microenvironment (Fig 2-2 C).    Many in vitro T cell studies have examined nutrient 
depletion on total T cells isolated from the blood or spleens of mice or humans.  
However, naïve cells that often represent the majority of T cells in circulation or in the 
spleen do not travel to sites of inflammation where vasculature is often disturbed or 
injured (Klebanoff et al., 2006; Thome et al., 2014). Differentiated effector memory T 
cells or tissue resident memory T cells are the cells that reside in the environments that 
actually encounter nutrient depletion and have distinct responses to metabolic stress 
(Dimeloe et al., 2016a; Ecker et al., 2018).  Thus, many previous studies have lacked 
sufficient resolution to determine whether T cells in the blood mimic the same 
metabolic and adaptive features of T cells that reside in the tissue.   
Missing spatial organization of nutrient availability and immune function 
There remain large gaps in understanding of immune cell localization within 
hypoxic or glucose depleted regions of tumors.  Do we truly observe anti-tumor function 
and immune cell proliferation only in sites of nutrient availability?  Do immune cells 
23 
 
have higher rates of death in sites of nutrient depletion or do they simply traffic away 
from those sites?  Which nutrients are the most essential for function in vivo?  Regions 
of nutrient depletion can often be examined through florescent analogues like 2-NBDG 
for glucose distribution, staining with pimonidazole for regions experiencing hypoxia, or 
through distinct protein expression of hypoxic or nutrient depleted cells  (Airley et al., 
2001).  These are well validated, and compatible with commonly used methods to 
identify immune cell localization and activity (Bennewith and Durand, 2004; He et al., 
2008; Sukumar et al., 2013).  Improvements in the resolution of mass spectrometry 
imaging techniques have also identified tissue-resident immune populations and 
metabolite gradients in tumors (Dilillo et al., 2017; Holzlechner et al., 2017).  
Additionally, sensitive reporter constructs could be useful to map the duration and 
regional location of nutrient limiting milieus.   Elucidating the spatial organization of 
nutrient availability and immune populations will be crucial for greater insight of 
immune surveillance in the tumor microenvironment (Fig 2-2 D).   
The last decade of research has led to incredible findings and a growing interest 
in immunometabolism.  Researchers have only just begun to understand how to 
translate the basic findings into in vivo tumor models and face many challenges.  Future 
studies designed to overcome these challenges will be essential for providing 
mechanistic understanding of in vivo immunometabolism and for translating these 
approaches into the clinical arena.   
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Figure 2-1:  Metabolic challenges T cells encounter in the solid tumor 
microenvironment.  
A. Nutrient limitation and competition.  Disturbed vasculature of solid tumors are often 
unable to provide nutrients critical for T cell activation.   Activated T cells and 
proliferating tumor cells rely on aerobic glycolysis and compete for extracellular glucose.  
B.  High extracellular lactate concentrations.  Reliance on aerobic glycolysis by tumor 
cells promotes a large buildup of the waste product lactate in the extracellular milieu of 
solid tumors.  High extracellular concentrations of lactate hinder T cell activation by 
inhibiting efficient secretion of lactic acid from the cytoplasm and acidifying intracellular 
pH.  C.  Hypoxia and MDSC-induced ROS. T cells in the solid tumor microenvironment 
are constantly exposed to reactive oxygen species, which are highly reactive and 
damage cellular structures.  Hypoxia rapidly induces ROS production by T cells and 
myeloid derived suppressor cells frequently suppress effector T cells by secreting ROS.  
D.  Decreased mitochondrial mass and function.  Tumor specific T cells have defects in 
mitochondria biogenesis, size, cristae structure, voltage potential and function.  E.  
Terminal differentiation and exhaustion.  Chronic antigen exposure causes loss of co-
stimulatory receptors while promoting inhibitory co-receptors that inhibit glycolytic 
metabolism and activation signaling.   
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Figure 2-2:  Challenges of applying immunometabolism findings to tumor models in 
vivo.   
A. Many researchers have found ways to improve anti-tumor efficacy of adoptively 
transferred T cells through metabolic manipulation or genetic engineering.  Too often 
though we lack the resolution to distinguish the mechanism by which enhanced tumor 
efficacy is reached.  B.  The speed by which cells metabolically adapt to changes in the 
extracellular environment during extraction procedures, and how quickly some 
metabolites can decay or be lost in commonly used isolation techniques hinder our 
understanding of in vivo biology. C.  The most accessible cells in the blood or spleen 
(that are commonly used in metabolic studies of nutrient limitation) do not reflect the 
metabolic traits or adaptive properties of terminally differentiated cells found in most 
tumors.  D.  The field has not explored the spatial organization of nutrient depletion and 
immune cell infiltration in solid tumors.   
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Chapter 3-Differential reliance on lipid metabolism as a salvage 
pathway underlies functional differences of T cell subsets in 
nutrient poor environments. 
Parts of this chapter were previously published in: 
Christopher Ecker, Lili Guo, Stefana Voicu, Luis Gil-de-Gómez, Andrew Medvec, Luis 
Cortina, Jackie Pajda, Melanie Andolina, Maria Torres-Castillo, Jennifer Donato, Sarya 
Mansour, Evan R. Zynda, Angel Varela-Rohena, Ian Blair, James Riley.  Differential 
reliance on lipid metabolism as a salvage pathway underlies functional differences of T 
cell subsets in poor nutrient environments.  Cell Reports. 2018. 
Andrew Medvec, Christopher Ecker, Hong Kong, Emily Winters, Joshua Glover, Angel 
Varela-Rohena, James Riley.  Improved Expansion and In Vivo Function of Patient T Cells 
by a Serum-Free Medium.  Mol Ther Methods Clin Dev.  2017. 
Introduction 
T cell responses against tumor are often blunted by the recruitment of 
suppressive immune cells, immune checkpoint blockade, exhaustion, and competition 
for vital nutrients (Chang et al., 2015a; Dunn et al., 2002; Jacobs et al., 2008; Moon et 
al., 2014; Sukumar et al., 2015).  Both tumor cells and activated effector T cells rely 
heavily on glycolysis, and recent work has demonstrated that tumor cells are able to 
outcompete T cells for scarce glucose (Chang et al., 2015b; Ho et al., 2015a).  The most 
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well-characterized defect in effector response due to poor glucose availability is the 
pronounced reduction in IFNγ production following activation of T cells (Cham and 
Gajewski, 2005; Chang et al., 2013; Siska et al., 2016).   Two mechanisms behind 
glucose-mediated IFNγ down-regulation have been proposed including: 1) GAPDH, when 
not involved in glycolysis, binds to the 3’ UTR of IFNγ and prevents IFNγ RNA from being 
translated (Chang et al., 2013); and 2) the steady state levels of cytosolic acetyl-CoA is 
reduced in limiting glucose, reducing histone acetylation at sensitive sites like the IFNγ 
locus and thus lowering production of IFNγ (Peng et al., 2016).  However, it is unclear 
whether either of these two mechanisms is operative, and equally active, in all T cell 
subsets. 
Most data studying T cell responses in the presence of limiting glucose have used 
cells which are largely naïve (TN) cells rather than human effector memory (TEM) cells 
which are the population enriched in the tumor microenvironment (Beura et al., 2016).  
T cell subsets have remarkably different proliferative capacities, trafficking patterns, and 
effector capabilities (Sallusto et al., 1999).  TEM cells are defined by the lack of lymphatic 
homing markers such as CCR7 and CD62-L and loss of the co-stimulatory molecule CD27.  
TEM cells do not proliferate well relative to naïve or central memory T cells (TCM) but 
have enhanced effector functions such as cytotoxic potential and effector cytokine 
production. 
Few studies have examined the metabolism of human TEM cells because they are 
difficult to culture and scarce in the peripheral blood of healthy donors.  The studies 
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that have been performed have demonstrated that TEM cells in hypoxia have a survival 
advantage and are uniquely adapted to produce IFNγ rapidly (Dimeloe et al., 2016b; 
Gubser et al., 2013; Xu et al., 2016).   Human TEM cells are the most common T cell to 
reside in the tumor microenvironment and other inflamed environments (Farber et al., 
2014; Pagès et al., 2005; Thome et al., 2014).  Inflammation often disrupts the 
vasculature and can induce hypoxia and deprive cells of valuable nutrients in the 
inflamed tissue (Eltzschig and Carmeliet, 2011). Thus, TEM cells are often forced to 
function in environments that are nutrient deprived.  We hypothesized that because TEM 
cells must function in nutrient deprived environments, they may have unique metabolic 
mechanisms to adapt compared to TN or TCM cells. Recent work has shown that fatty 
acid oxidation and synthesis is essential for survival, growth, and metastatic expansion 
of pancreatic cancer and other cancer cells in vivo (Ricciardi et al., 2015; Samudio et al., 
2010; Svensson et al., 2016).  We speculated that if pancreatic cancer cells became 
reliant on fatty acids, T cells found in the same limited nutrient environment might rely 
on a similar metabolism.  
Here we demonstrate like many cancer cells, when TN and TCM cells are starved of 
glucose, they augment fatty acid metabolism which drives oxidative phosphorylation 
and allows these two T cell subsets to survive in limited glucose.  This increased reliance 
on fatty acid oxidation and synthesis correlated with reduced IFNγ expression upon T 
cell activation.  In contrast, TEM cells did not upregulate fatty acid synthesis and could 
maintain high levels of IFNγ production in low glucose upon T cell activation.  Together, 
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these data suggest that TEM cells are programmed to have limited ability to synthesize 
and metabolize fatty acids and as a result TEM cells maintain functionality in limiting 
glucose conditions. 
Results  
Generation of a chemically-defined, customizable medium that can expand human T cell 
subsets in the absence of serum 
To date, studies that have examined the effects of nutrient availability on T cell 
function in vitro have relied on media supplemented with dialyzed serum (Blagih et al., 
2015; Chang et al., 2013; Keppel et al., 2015).   Serum is ill-defined, making 
characterization of key nutrients challenging. Moreover, dialysis of serum is nonspecific.  
To overcome these limitations, we sought to create a chemically-defined medium that 
could expand all human T cell subsets without supplementation of human serum.  Three 
different basal media that contained selected groups of components, including fatty 
acids, metal elements, polyamines, and antioxidants were generated for the study. 
These media were used alone or mixed at different ratios to generate ten media for the 
Design of Experiments (DOE) screen (Fig 3-1 A, Table 3-1 A).  T cells from seven healthy 
donors were activated with anti-CD3/CD28 coated beads and their expansion rates were 
monitored in each of the ten media (Fig 3-1 B). Statistical analysis, harmonization to 
eliminate components of xenogeneic origin, and rational approaches based on spent 
media samples were used to further optimize the media (Fig 3-1 C, D, Table 3-1 B, C). 
Lastly, using a range of concentrations of glucose, galactose, and lipids, the carbon 
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source supplied to the T cells was optimized (Fig. 3-1 E, Table 3-2) and compared to that 
of medium actively being used in clinical trials of adoptive T cell therapy, X-VIVO 15TM 
media supplemented with 5% human serum.   
There is no consensus on what is the best media to use for adoptive T cell 
therapy; however, most groups to date have used RPMI 1640, AIM V, or X-VIVO 15 
media (Cruz et al., 2013; Lee et al., 2015; Maude et al., 2015).  Both AIM V and X-VIVO 
15 are defined as serum-free media, but in the T cell manufacturing process used to 
treat patients, human serum is universally added, largely because patient-derived T cells 
fail to grow optimally in serum-free media and exhibit reduced efficacies of gene 
transfer resulting from less than optimal T cell activation.  We decided to examine which 
medias could maximally expand human T cells in the absence of human serum.  As 
expected, RPMI 1640 required the addition of human serum to promote T cell 
expansion (Fig 3-2 A). T cells expanded in AIM V grew as well as T cells expanded with 
AIM V supplemented with human serum for 5 days. However, after 5 days, AIM V SFM 
could not support further T cell expansion (Fig 3-2 B). In contrast, both X-VIVO 15 and 
1B2H supported T cell expansion nearly equivalently in the presence and absence of 
serum, although it is important to note that T cells expanded in the absence of serum 
rested more quickly than T cells expanded in the presence of serum.  (Fig 3-2 C, D). 
Thus, both X-VIVO 15 and 1B2H fulfill the requirement of being a bona fide serum-free 
medium: similar expansion in the presence and absence of human serum. 
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An in vivo model of CAR T cell therapy was developed, which has proven 
informative for predicting clinical results in humans (Grupp et al., 2013; Kalos et al., 
2011; Porter et al., 2011).  In this model, NALM6, a pre-B cell leukemic cell line that 
naturally expresses CD19, was engineered to express luciferase and engrafted into 
NOD/SCID-γc−/− (NSG) mice. If CD19-specific CAR T cells are added within a week, tumor 
clearance is observed within 10–14 days. However, if the experiment is extended, 
leukemia returns in most animals and durable cures are not observed. We sought to 
determine whether T cells expanded in 1B2H could perform in vivo as well as T cells 
expanded using X-VIVO 15 supplemented with 5% human serum—the current medium 
formulation our group uses for good manufacturing practice (GMP) manufacturing of 
T cells. Consistent with previous findings, we observed that CD19-specific CAR T cells 
expanded in X-VIVO 15 supplemented with 5% human serum dramatically cleared 
tumors from NSG mice 13 days after the infusion of T cells (Fig 3-3 A) (Milone et al., 
2009). However, as previously demonstrated, this control was transient, with tumor 
returning to most of the mice. Surprisingly, CD19-specific CAR T cells expanded in 1B2H 
SFM could provide durable control of tumors and this translated to a remarkable 
difference in leukemia-free survival (Fig 3-3 B). Interestingly, mice treated with CAR 
T cells expanded with 1B2H supplemented with 5% human serum could only transiently 
control tumor burden similarly to mice treated with CAR T cells expanded in X-VIVO 15 
supplemented with 5% human serum, suggesting that expanding T cells in the presence 
of serum is detrimental to in vivo performance of engineered T cells. Both humanized 
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mouse studies and clinical data from patients have shown a strong correlation with the 
level of T cell persistence after adoptive transfer and the ability to provide durable 
control of tumors (Maude et al., 2014; Milone et al., 2009). Likewise, we observed 
superior T cell engraftment that was sustained for much longer in cells expanded in the 
absence of serum (Fig 3-3 C, D). Together, these data suggest that human serum is not 
only dispensable, but is also hindering the ability of CAR T cells to function, persist, and 
control tumor growth. 
 Traditionally most CAR studies have focused on ex vivo transduction and 
expansion and subsequent autologous transfer of a patient’s own cells, which are highly 
differentiated and poorly proliferative compared to a healthy donor’s T cells.  Thus we 
examined the functional properties of the multiple myeloma patient T cells expanded in 
X-VIVO 15 or 1B2H, with and without serum. Here, the addition of serum did not 
significantly alter the functional profile of the expanded CD19-specific CAR T cells 
because there were no consistent differences between T cells grown in 1B2H or X-VIVO 
15 (Fig 3-4 A, B), suggesting the functional abilities of fully differentiated T cells are not 
modulated by the presence of human serum or media in which they are expanded. We 
then addressed the ability of these expanded T cells to control NALM6 tumors in vivo. As 
a control, we also expanded CD19-specific T cells from a healthy individual so we could 
compare in vivo function of T cells from healthy donors and multiple myeloma patients. 
All T cell populations showed transient control of NALM6 tumors; however, 2 of the 6 
mice that were treated with T cells expanded by X-VIVO 15 SFM still had significant 
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tumor burden after 12 days of treatment (Fig 3-4 C) and none of these mice durably 
controlled tumor growth (Fig 3-4 D). As before, the leukemia relapsed in most mice 
treated with CD19-specific T cells expanded in either 1B2H or X-VIVO 15 supplemented 
with human serum. Impressively, T cells isolated from multiple myeloma patients 
engineered to be CD19 specific and expanded in 1B2H SFM provided durable control of 
tumor in all mice treated and had equivalent therapeutic potency as similarly 
engineered and expanded T cells isolated from a healthy donor. 
While physiological glucose concentration in human blood is around 5mM, we 
found that the static optimal glucose concentration that allowed maximal T cell 
expansion and maintained high glucose concentrations throughout culture conditions is 
35mM (Table 3-2). To ensure that our medium, called 1B2H, could be customized to 
study T cell metabolism, we generated 1B2H variants that were glucose or glutamine 
free.  We found that T cells could not divide in media free of glucose or glutamine, 
demonstrating that our media contained no nutrients that could substitute for either 
glucose or glutamine (Fig 3-5 B).  To examine how well human T cell subsets grew in our 
created medium in the absence of serum, we sorted TN, TCM and TEM CD4 T cells and 
compared expansion in our created medium (1B2H) supplemented with or without 
human serum.  We found that all subsets could grow equally well in 1B2H medium with 
or without serum supplementation (Fig. 3-5 C-E), and this level of T cell expansion is 
consistent with serum supplemented commercial media that is currently being used for 
adoptive T cell therapy (Medvec et al., 2018).  Thus, 1B2H is a bona fide serum-free, 
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medium that can facilitate the study of metabolic differences between human T cell 
subsets. We were able to utilize our collaboration with Thermofisher Scientific to further 
customize this defined media to add and withdraw specific nutrient components 
specifically, without the need for dialysis. 
Effector Memory T cells are resistant to glucose-mediated IFNγ suppression 
We next examined how low glucose altered human T cell subsets’ ability to 
expand, adapt functionally, and differentiate.    We sorted TN, TCM, and TEM (Fig 3-6 A-I) 
and stimulated them with anti-CD3/CD28 coated beads in the presence of optimal 
glucose (35mM) or low glucose (0.35mM).    As expected, all T cell subsets have 
substantially reduced growth in low glucose (Fig 3-7 A).   We next examined the ability 
of freshly sorted human T cell subsets to produce IFNγ in the presence of optimal or low 
glucose after PMA/ionomycin stimulation.  TN and TCM cells made less IFNγ in low 
glucose, consistent with previous reports (Cham and Gajewski, 2005; Chang et al., 2013; 
Chang et al., 2015b; Ho et al., 2015a).   However, TEM cells made equivalent levels of 
IFNγ (Fig 3-7 B, E), suggesting that the effector functions of TEM cells are not 
compromised in poor nutrient environments.  Interestingly IL-2 and TNFα (Fig 3-7 B,C, 
Fig. 3-8 A-F) are not affected by glucose availability.  Therefore, we expanded T cells 
from Fig 3-7B for 10-12 days and determined their ability to make IFNγ and IL-2 upon re-
stimulation.  We observed expanded TN cells still have a profound defect in their ability 
to produce IFNγ in low glucose, whereas both expanded TCM and TEM cells produced 
equivalent IFNγ after being expanded in both optimal and low glucose (Fig 3-7 C, F). The 
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ability of expanded but not freshly isolated TCM cells to make high levels of IFNγ in the 
presence of optimal or low glucose is likely tied to their more differentiated phenotype 
after expansion (Fig 3-7 D, G, H).  Furthermore, we found that while all cells up-regulate 
CD25, the IL-2 receptor, following anti-CD3/CD28 bead activation in both optimal and 
low glucose, TN and TCM cells lost CD25 expression quickly following activation in low 
glucose whereas TEM cells were able to maintain heightened CD25 expression in limiting 
glucose (Fig 3-9 A-D), suggesting that they can maintain an activated phenotype in poor 
nutrient conditions.  Cumulatively these data show that TEM cells maintain function in 
low glucose whereas TN and TCM make less IFNγ and lose CD25 expression. 
Effector memory T cells do not augment oxidative phosphorylation in low glucose 
Past studies have linked T cell metabolism to IFNγ production (Cham and 
Gajewski, 2005; Chang et al., 2013; Ho et al., 2015a).  To better understand the 
relationship between T cell metabolism and function, we performed metabolic assays 
on activated human T cells cultured in media with 35mM, 3.5mM, 0.35mM or no 
glucose.  In agreement with previous studies, we found that T cells cultured in lower 
amounts of glucose had reduced glycolysis as measured by extracellular acidification 
rate (ECAR) and compensated for this loss in glycolysis by up regulating oxidative 
phosphorylation measured by oxygen consumption rate (OCR, Fig 3-10 A, B).  Previous 
reports have demonstrated the importance of fatty acid oxidation in T cells to their 
ability to utilize and upregulate their OCR (O'Sullivan et al., 2014; van der Windt et al., 
2012).  We also found that OCR increases were dependent upon fatty acid oxidation as 
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the increase in OCR in limiting glucose was blocked by etomoxir, a drug that blocks fatty 
acid intake into the mitochondria by inhibiting carnitine palmitoyltransferase (Fig 3-10 
D).  However, etomoxir treatment did not significantly alter ECAR, intracellular lactate or 
extracellular lactate production (Fig 3-10 C, G, H). TN and TCM cells behave in a similar 
fashion to total T cells by exhibiting reduced glycolysis and augmented OCR when 
cultured in low glucose (Fig 3-10 E, F). Furthermore, etomoxir inhibited the OCR of all T 
cell subsets only in low glucose, without altering their glycolytic rate (Fig 3-10 I-N).   
These data show that effector memory T cells metabolically respond to low glucose 
distinctly from other T cell subsets by not augmenting oxidative metabolism.   
Effector memory T cells contain fewer lipid droplets than other T cell subsets in optimal 
glucose 
Because TN and TCM, but not TEM could compensate for low glucose by 
augmenting oxidative phosphorylation in a fatty acid dependent manner, we wanted to 
examine the supply of lipids stored within the cell.  Lipid droplets are dynamic 
organelles that play a key role in the regulation of lipid metabolism and serve as a ready 
to use source of lipids (Barneda and Christian, 2017).  We first isolated total CD4 T cells 
and examined the number of lipid droplets in resting and activated cells in both optimal 
and low glucose.  T cell activation was required for the formation of lipid droplets as we 
did not observe lipid droplets in resting T cells. Moreover, we found that activated CD4 T 
cells grown in optimal glucose had dramatically more lipid droplets per cell than cells 
activated in low glucose (Fig 3-11 A, F). We hypothesized that T cells expanded in low 
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glucose could not store lipid droplets, because they were using lipids as fuel for 
oxidative phosphorylation.  To determine whether lipids were being consumed in T cells 
when cultured in low glucose, we first activated T cells in optimal glucose for 48 hours, 
and then placed them in low glucose for an additional 0, 4, 8, 24, or 48 hours.  We 
further quantified lipid droplets by staining cells with the lipophilic dye bodipy 493/503 
which is commonly used to mark neutral lipids (Singh et al., 2009).   Significant 
decreases in bodipy florescence of stained lipid droplets were observed after placing 
cells in low glucose for greater than 24 hours, indicating that T cells consume lipid 
droplets when placed in nutrient poor conditions (Fig 3-11 B, Fig 3-12 A). After 6 days of 
culture, we observed significant number of autophagosomes (Fig 3-12 B).  Under normal 
conditions autophagic protein microtubule-associated protein 1 light chain-3B (LC3B) 
consists largely of its cytoplasmic form LC3B-1.  However during autophagy, LC3B 
becomes conjugated to phosphatidylethanolamine forming  LC3B-II and is recruited to 
the membrane of autophagosomes (He et al., 2003).  We found that T cells cultured in 
optimal glucose maintained higher levels of LC3B-I compared to LC3B-II whereas T cells 
cultured in low glucose had much more LC3B-II than LC3B-I (Fig 3-11 C-E, Fig 3-12 D-E), 
confirming that T cells were performing autophagy in response to low glucose.   
Previous studies have implicated autophagy in fatty acid consumption (Liu and 
Czaja, 2013; Singh et al., 2009).  We found that T cells were unable to consume their 
lipid droplets in low glucose when treated with an autophagy inhibitor, Lys05 (Fig 3-12 
C).   To further investigate whether autophagy was responsible for the breakdown of 
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lipid droplets, we transduced T cells with a lentiviral vector expressing LC3B fused to 
mCherry, a pH insensitive fluorescent reporter.  We found that lipid droplets marked by 
bodipy 493/503 often co-localized with the autophagosomes (Fig 3-11 D), suggesting 
that autophagy was responsible for lipid droplet breakdown and consumption.  
Furthermore, we found that inhibiting mTORC1 via rapamycin, a well-known method of 
inducing autophagy, increased T cell growth in low glucose but not in optimal glucose.  
We found that the enhanced growth by rapamycin was blocked when co-administering 
Lys05, while expansion was not significantly inhibited by Lys05 alone in low glucose (Fig 
3-12 F-H). These data support the idea that promoting autophagy can increase T cell 
expansion in low glucose possibly by increasing lipid consumption.  Next, we isolated T 
cell subsets to examine if TEM cells may fail to up-regulate oxidative phosphorylation 
because they cannot uptake lipids and store them as well as TN or TCM cells. We observed 
TN and TCM cells cultured in optimal glucose had significantly higher amounts of lipid 
droplets per cell per micrograph than TEM cells (Fig 3-11 E, G).    These data demonstrate 
that TEM cells acquire fewer lipid droplets in optimal glucose, suggesting that lipids may 
not be the preferred alternative fuel for TEM. 
Effector memory T cells are unable to perform reductive glutaminolysis for fatty acid 
synthesis when cultured in low glucose 
Next, we wished to examine whether other salvage pathways were differentially 
regulated in T cell subsets in response to low glucose.  An increased consumption of 
glutamine has been shown to be a salvage pathway to drive T cell metabolism in low 
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glucose (Blagih et al., 2015). We quantified the rates of consumption/production of 
glucose, amino acids and a few organic acids in the supernatant of activated T cells 
(Table 3-3 A, B).  As expected, T cells primarily consumed glucose and glutamine.  
Additionally, we observed high consumption of serine, supporting recent findings that 
serine is essential for de novo nucleotide biosynthesis (Ma et al., 2017a). T cells in low 
glucose regardless of subset, consumed fewer amino acids, likely due to overall reduced 
level of T cell activation.  Interestingly glutamine was equally consumed by T cells at 
optimal or low glucose; thus, relative to other amino acids, glutamine was preferentially 
consumed by T cells cultured in low glucose.  Surprisingly, TCA cycle intermediates 
demonstrated different patterns of abundance, suggesting complex regulation of the 
TCA under nutrient stress (Fig 3-13 A-G). To examine how glutamine was utilized, we 
cultured T cells in the presence of labeled glutamine and examined how it was 
metabolized within the cell.   The differential labeling of citrate can be used to interpret 
glutamine metabolic pathways (Fig 3-14 A) (Fendt et al., 2013; Metallo et al., 2011).  A 
citrate with 4 heavy carbons (marked mass +4 or M+4) suggested typical oxidative 
glutaminolysis, where glutamine is incorporated into the TCA cycle and then spread 
across other TCA cycle intermediates. We found that T cells cultured in low glucose had 
less labeled M+4 citrate and this was observed in all T cell subsets examined (Fig 3-14 
B).  To extend this finding, we examined other TCA intermediates and found equivalent 
levels of M+4 labeling, suggesting that oxidative glutaminolysis functions similarly in all T 
cell subsets in both optimal and low glucose (Fig 3-14 E-G).  
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A citrate with 5 heavy carbons suggests reductive glutaminolysis where 
glutamine is being routed into fatty acid synthesis (Fig 3-14 B). We found that TN and 
TCM cells had higher relative amounts of citrate M+5 when cultured in low glucose, 
suggesting that some of the glutamine imported into T cells was being converted to 
fatty acids (Fig 3-14 A). TEM cells, on the other hand, did not to appear to upregulate 
fatty acid synthesis in the presence of low glucose since the relative percentage M+5 
was the same regardless of the T cells being cultured in optimal or low glucose.  To 
confirm this, we examined both M+2 and M+4 palmitate which would directly show 
glutamine being converted to fatty acids.  Interestingly, we observed that TN and TCM 
cells expanded in optimal glucose had higher levels of M+2 palmitate than their 
respective groups grown in low glucose, but higher M+4 palmitate (Fig 3-14 H-J).  In 
contrast, TEM cells have low levels of M+2 palmitate when cultured in both optimal and 
low glucose, suggesting that very little glutamine gets converted to fatty acids in TEM 
regardless of the glucose levels present.  These data indicate that reductive 
glutaminolysis is occurring at a higher rate in TN and TCM cells cultured in low glucose.  
Only small amounts of M+4 palmitate was detected in TEM cells further confirming very 
little glutamine is converted to fatty acids in TEM regardless of the glucose levels present.    
A citrate with 6 heavy carbons suggests that some fraction of glutamine is being 
converted into pyruvate and this pyruvate is then being used to generate citrate (Fig 3-
14 A).  We found that all T cell subsets expanded in low glucose had higher levels of 
citrate M+6, indicating that the differential use of glutamine by TEM cells is confined to 
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reductive glutaminolysis (Fig 3-14 D).   Interestingly, all T cells subsets redirect glutamine 
into production of pyruvate by having increased M+3 labeling of pyruvate, making an 
estimated 20% of the intracellular pool in low glucose (Fig 3-14 K).  Additionally, ~10% of 
the intracellular pool of lactate is made from glutamine, suggesting that this glutamine-
derived pyruvate is converted into lactate (Fig 3-14 L).  We found that all subsets when 
cultured in optimal glucose secreted approximately 1.5 moles of lactate per mole of 
glucose consumed, consistent with previous reports showing that most of the glucose 
utilized is converted into lactate (Frauwirth et al., 2002).  However, when T cells were 
cultured in low glucose, we found that lactate/glucose ratios exceeded 2, suggesting 
that a carbon source other than glucose was being used to produce lactate (Fig 3-14 M). 
Together, T cells appear to be adept at using glutamine to fulfill a diverse array of 
metabolic needs when glucose is limiting with the notable exception that TEM cells are 
unable to use glutamine to produce fatty acids. 
Effector memory T cells are less reliant on fatty acid metabolism for survival and 
expansion at low glucose 
With evidence of fatty acid droplets being consumed in low glucose and data 
demonstrating that glutamine was being redirected into fatty acid synthesis by TN and 
TCM cells, we sought to explore the importance of fatty acid metabolism for the survival 
and expansion of T cells in low glucose.   We treated activated T cells in optimal or low 
glucose with 5-(Tetradecyloxy)-2-furoic acid (TOFA), an inhibitor of fatty acid synthesis, 
or vehicle (DMSO).  We saw little to no effect of TOFA on T cell expansion in optimal 
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glucose and significant inhibition of T cell expansion in low glucose (Fig 3-15 A, B).   We 
further examined how TOFA affected the expansion of T cell subsets grown in low 
glucose.  TN and TCM cells behaved in a similar manner to total T cells and suffered 
severe proliferative defects when cultured in low glucose (Fig 3-15 C).  In contrast, 
expansion of TEM cells was only marginally affected by TOFA in both optimal and low 
glucose.  However, T cells can also uptake fatty acids from exogenous sources 
(O'Sullivan et al., 2014).  We quantified surface expression of CD36, a scavenger 
receptor that is thought to be important for uptake of long-chain fatty acids (Glatz and 
Luiken, 2016; Schwenk et al., 2010).  We observed that TN and TCM cells could up-
regulate CD36 when grown in low glucose, while TEM cells did not (Fig 3-15 D-E).  
Together these data suggest that TEM cells are not as reliant as TN or TCM cells on fatty 
acid synthesis or uptake of exogenous fatty acids to expand in limiting glucose. 
 To further characterize which T cell subsets, if any, are dependent on exogenous 
fatty acids we prepared fully defined, serum free media that lacked all species of lipids 
(Fat-Free).  Despite an early defect in proliferation, we found that total T cells in optimal 
glucose in the absence of lipids expanded nearly as well as T cells in the presence of 
lipids (Fig 3-15 F). However, in low glucose, the lack of fatty acids severely impaired T 
cell expansion. This pattern remained consistent in TN and TCM cells, their expansion was 
severely inhibited in fat free media when grown in low glucose (Fig 3-15 G).   
Surprisingly, TEM cells grew equally well in the presence and absence of lipids in low 
glucose.  Next, we wanted to quantify how much different T cell subsets incorporated 
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exogenous lipids into the TCA cycle.  In agreement with our data in Figure 2, we found 
that all subsets equally increased their incorporation of exogenous fats into acetyl CoA 
(Fig 3-15 H). We examined the viability of T cells and observed that most of the TN and 
TCM cells were dead in low glucose, fat-free media whereas TEM cells had near equivalent 
viability in the presence and absence of lipids (Fig 3-15 I-J).  Cumulatively, these results 
show that TEM cells are not as reliant as TN or TCM cells on lipid metabolism to expand or 
survive in low glucose. 
Impairment of fatty acid synthesis in naïve T cells augments IFNγ expression 
Our data demonstrate a strong correlation between a T cell subset’s ability to 
utilize fatty acids and subsequent ability to produce IFNγ in limiting glucose.  To 
determine whether there is a relationship between IFNγ expression and fatty acid 
metabolism, we first asked whether a reduction in fatty acid synthesis would augment 
IFNγ production.  To do this, we used a dose of TOFA (5µM) that permits TN cells to 
survive in low glucose and then examined their ability to make IFNγ.  Blocking fatty acid 
synthesis in TN cells significantly increased their ability to make IFNγ (Fig 3-16 A,B).  This 
did not however impact TEM cells ability to produce IFNγ, further confirming the notion 
that TEM cells are not actively synthesizing fatty acids and thus are insensitive to TOFA.  
Interestingly, blocking fatty acid synthesis did not impact the production of other 
cytokines such as IL-2 in any of the subsets (Fig 3-16 C), suggesting that IFNγ is 
specifically targeted by fatty acid metabolism.  Furthermore, TOFA did not alter IFNγ or 
IL-2 production in TN cells or any other subset in optimal glucose (Fig 3-17 A, B).  This is 
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consistent with our mass spectrometry data, suggesting that T cells activated in optimal 
glucose do not utilize fatty acid synthesis to a significant extent.   
Next, we sought to determine whether increasing the concentration of 
exogenous lipids in the media would cause decreased production of IFNγ by T cells. To 
do this, we added a defined minimal lipid concentration that permitted T cell expansion 
in low glucose to our lipid-free media.  To investigate how individual subsets reacted to 
the presence of exogenous lipids, we added increasing doses of exogenous lipids to 
sorted subsets and examined IFNγ and IL-2 production.  We found that in minimal lipids, 
IFNγ production by all subsets was higher than that of cells in normal amounts of lipids 
(1x) in low glucose (Fig 3-16 D, E).  Furthermore, we found that as we increased lipid 
concentration, IFNγ production further decreased in all subsets. Moreover, the addition 
of exogenous lipids caused decreases in not only IFNγ but also IL-2 in TN and TCM cells 
but not TEM cells (Fig 3-16 C-F), further highlighting TEM cells’ relative resistance to 
modulate their effector functions due to fatty metabolism. Together, these data 
demonstrate that lipid metabolism regulates IFNγ production. 
Decreased mitochondrial mass in lung T cells in non-small cell lung cancer patients 
In recent months we have asked how our new data on effector memory T cell 
metabolism may apply to tumor infiltrating lymphocyte (TIL) metabolism.  Through a 
collaboration with Steve Albelda’s group, we have been able to receive human samples 
from non-small cell lung cancer (NSCLC) patients .  We are able to isolate CD4 and CD8 T 
47 
 
cells from the blood, adjacent lung tissue , and tumor tissue within the lung.  Recent 
work has demonstrated that TILs (which are mostly terminally differentiated cells with 
similar phenotype to effector memory T cells) have lower mitochondrial mass compared 
to T cells in the  blood, spleen or lymph node (Scharping et al., 2016).  Furthermore the 
remaining mitochondria are often dysfunctional and hyperpolarized due to chronic 
antigen exposure and tumor-intrinsic singals (Bengsch et al., 2016; Siska et al., 2017b).  
Because our data suggests T cells may utilize mitochondrial-related pathways during 
glucose deprivation in the tumor microenvironment, we examined the mitochondrial 
mass of T cells from NSCLC patient blood, adjacent lung tissue, and tumor tissue.  In 
agreement with earlier findings, we find that CD8+ T cells (and to some extent CD4+ T 
cells) have a severe defect in mitochondrial mass in the tumor compared to T cells from 
the peripheral blood (Fig 3-18 A-D).    Surprisingly though we found this mitochondrial 
mass defect affected the adjacent lung, and not only the T cells present within the 
tumor.  Furthermore, differentiation was not significantly responsible for these 
mitochondrial mass differences (Fig 3-18 E).  This data may suggest that there are tissue-
specific signals and not tumor-specific signals that alter mitochondrial mass.  
Furthermore, we are currently working to examine how decreased mitochondrial mass 
impact TIL reliance on mitochondrial pathways during glucose limitation. 
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Discussion  
Over the past few years, it has become increasingly clear that T cell metabolism 
plays a crucial role in driving T cell differentiation and function (Pollizzi and Powell, 
2014). Our studies uncovered that T cell subsets respond distinctly to the same 
metabolic stress.  In response to low glucose, TN and TCM cells increase oxidative 
phosphorylation, rely on fatty acid metabolism, increase autophagy, and redirect 
glutamine into pathways that produce both fatty acids and pyruvate. We show that 
unlike TN or TCM cells, TEM cells do not rely on fatty acid synthesis or increase oxidative 
phosphorylation in low glucose.  We further demonstrate that by being less reliant on 
fatty acid pathways TEM cells can maintain functionality during nutrient stress (Fig 3-19 
A,B).   
Our studies suggest that the relative ratio of glycolysis to fatty acid metabolism 
within a single effector T cell determines its functional capabilities.  By limiting fatty acid 
metabolism in TN, we could significantly augment their IFNγ production.  Conversely, by 
culturing TEM in high levels of lipids, we selectively decreased their ability to make IFNγ.  
Thus, our studies show a strong link between active fatty acid metabolism and the 
ability to make IFNγ, adding to a number of mechanisms a T cell employs to regulate 
IFNγ production (Chang et al., 2013; Peng et al., 2016; Siska and Rathmell, 2016). There 
are many challenges associated with translating in vitro findings on T cell metabolism to 
in vivo models (Ecker and Riley, Submitted).  Simple adoptive transfer studies favor less 
differentiated T cell due to their ability to expand and differentiate into effector 
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memory T cells (Gattinoni et al., 2011).  Models in which the metabolic milieu and the 
number infiltrating T lymphocytes can be carefully controlled and monitored will be 
necessary to confirm our findings in vivo.  To date, the best in vivo data supporting our 
in vitro studies comes from studies that correlate the number of TEM within the tumor 
microenvironment with patient survival (Farber et al., 2014; Pagès et al., 2005; Thome 
et al., 2014). 
Immune cells are one of the few groups of cells in the body that must travel to a 
wide-spectrum of environments. These environments have a diverse array of metabolic 
requirements and immune cells must be able to function in all of them.  Our work and 
others demonstrate that T cells can downregulate activation, proliferation, and 
transcription to lower energy consumption, while relying on salvage pathways to utilize 
diverse fuel sources (Blagih et al., 2015).  Previous work has demonstrated that glucose 
is not only essential for generating energy quickly through glycolysis but glycolytic 
intermediates are necessary for effective T cell activation and proliferation (Ho et al., 
2015a). Thus, these salvage pathways do not simply need to meet the energy demands 
for the cell when traditional nutrients are scarce, but need to supply the building blocks 
to generate proteins, fatty acids and nucleic acids required for T cell expansion and 
differentiation (Pearce and Pearce, 2013).  Our data that glutamine can be shunted into 
all metabolic pathways examined in glucose limiting conditions, driving increased 
oxidative phosphorylation and increased biosynthetic production of fatty acids and 
pyruvate, demonstrates how different carbon sources could be utilized in nutrient poor 
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conditions.  Increased oxidative phosphorylation in limiting glucose likely amplified the 
need for fatty acid oxidation and exogenous fatty. The incredible flexibility of T cells to 
manufacture the building blocks of many synthetic pathways underlies their ability to 
function throughout the body.  Our studies highlight how the salvage pathways that T 
cells choose to alter their eventual functionality.  Understanding the metabolic demands 
of T cell subsets and how to modulate traditional and salvage metabolic pathways may 
yield more effective cellular therapies for cancer and other diseases. 
Materials and Methods 
Study Design 
The purpose of this study was to characterize human T cell subsets and identify metabolic 
and functional outcomes when grown in sufficient and deficient conditions.  The number 
of replicates per experiment are indicated in the figure legends and performed in a 
controlled and non-blinded manner.   
Immune Cell Purification and Sorting  
De-identified human CD4 T cells were obtained from the Human Immunology Core at 
the University of Pennsylvania under an IRB approved protocol and stained using 
antibodies for CD4 (BD Pharmingen, 562424), CD45RA (BD Pharmingen, 337167), CD25 
(BD Pharmingen, 557138), CCR7 (Biolegend, 353218) and CD27 (Biolegend, 353218). 
Naïve (N, CD45RA+, CCR7+, CD27+, CD25-), central memory (CM, CD45RA-, CCR7+, CD27+, 
CD25-) and effector memory (EM, CD45RA-, CCR7-, CD27-, CD25-) were sorted to high 
purity using a BD FACS AriaII. 
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Cell Culture and Activation 
Sorted CD4 T cells were washed twice in PBS, and then placed in IB2H serum-free 
medium containing optimal (35mM), medium (3.5mM) or low (0.35mM) glucose 
concentrations.   The medium was supplemented with 1x (500uL), or 2x (1000uL) or 3x 
(1500uL) when indicated, of a chemically defined lipid mixture (ThermoFisher Scientific, 
11905031, individual lipid concentrations available online) and 8mM L-glutamine.   Cells 
were then activated at 1 million cells per mL using Dynabeads® Human T-Expander 
CD3/CD28 (ThermoFisher Scientific, 11131D) at a concentration of 3 beads per cell.  
Additional volumes of medium were added on Day 3 and every day after so that each 
culture was at 0.5 million cells/mL after feeding.  Cells were treated with TOFA (5, 
10μM, Sigma Aldrich, T6575), or etomoxir (200, 400 μM Sigma Aldrich, E1905).  cDNA 
encoding LC3B was synthesized (IDT) and transferred into pTRPE, a lentiviral transfer 
vector (Leibman et al, submitted).  Lentiviral supernatants and T cell transduction were 
generated and performed as previously described (Parry et al., 2003) 
Intracellular Cytokine Staining  
Sorted cells were treated with 1μg of PMA (Sigma Aldrich, P1585) per mL of media, 3μg 
of ionomycin (Sigma Aldrich, 407950) per mL of media and GolgiStop (BD Pharmingen 
554724) for 6 hours at 37OC immediately following sorting or 9-11 days post-activation 
after cells had rested and stopped dividing.  Cells were stained with Live/dead Aqua 
(ThermoFisher Scientific, L34957) according to manufacturer’s instructions.  Cells were 
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washed with 1x PBS, and fixed using Fixation Medium A (ThermoFisher Scientific, 
GAS001S100) for 15 minutes at room temperature.  Cells were then washed again with 
1x PBS.  Cells were then permeabilized using Permeabilization Medium B (ThermoFisher 
Scientific, GAS002S100) and stained with antibodies for IFNγ (eBioSciences, 45-7319-42), 
IL-2 (BD Pharmingen, 554567), and TNFα (BD Pharmingen 557647) for 15 minutes at 
room temperature.  Cells were then washed 1x with PBS, and analyzed using the BD LSR 
II flow cytometer. 
Western Blotting 
Cells were lysed with 1x RIPA Buffer (Cell Signaling Technology, 9806) and 1mM PMSF 
(Cell Signaling Technology, 8553S) according to manufacturer’s instructions.  Proteins 
were resolved by SDS-PAGE and transferred to nitrocellulose.  Blots were probed with 
anti-LC3B (Cell Signaling Technology, 3868) and anti-β-actin (Cell Signaling Technology, 
4970). Protein was visualized using Odyssey CLx LI-COR instrument.   
Confocal Microscopy 
To quantify neutral lipid droplets, cells were stained with 500n/mL Bodipy 493/503 
(ThermoFisher Scientific, D3922) in serum free medium at 37 degrees Celsius for 30 
minutes.  Cells were then washed 2x with PBS and placed in their respective media.  
Cells were live imaged at 37 degrees Celsius using a stage heater on the Leica TCS SP8 
Confocal microscope. 
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Metabolite extraction, derivatization and LC-MS measurements 
Cells were activated with anti CD3/CD28 beads in media supplemented with 8mM [U-
13C]-glutamine (Cambridge Isotope Laboratories, CNLM-1275-H-PK) for 48 hours when 
indicated. The isolation and LC-MS measurements of organic acids were performed as 
described previously with slight modification (Angelin et al., 2017; Guo et al., 2016). 
Briefly, cells were washed twice with PBS before extracting using 750 μL of ice-cold 
methanol/water (4/1 v/v). For metabolites quantification, samples were spiked with 
internal standards (250 ng [13C4]-succinate, 250 ng [13C6]- citrate, 250 ng [13C3]-pyruvate, 
1 μg [13C3]-lactate, 25 ng [ 13C4, 15N]-aspartate, 1 μg [13C5, 15N]-glutamate and 250 ng [ 
13C6]-glucose 6-phosphate). Samples were pulse-sonicated for 30 s with a probe tip 
sonicator and centrifuged at 16,000 g for 10 min. The supernatant was transferred to a 
new tube before evaporation to dryness under nitrogen. For quanitfying pyruvate, α-
ketoglutarate and oxaloacetate, 1 mg phenylhydrazine was included in the 750 μL 
methanol/water (4/1 v/v) for metabolite extraction. Samples were suspended in 50 μL 
before LC-MS analysis using an Agilent 1200 series high performance liquid 
chromatography system coupled to an Agilent 6460 triple quadrupole mass 
spectrometer equipped with an electrospray ionization source. Analytes were separated 
by reversed-phase ion-pairing chromatography utilizing a Xselect HSS C18 column (150 × 
2.1 mm, 3.5 μm, 100 Å; Waters). For samples that needed to be analyzed for the 
isotopic distribution of acetyl-CoA, cells were extracted using methanol/water as 
described above except that the samples were re-suspended in 50 μL of water with 5% 
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5-sulfosalicylic acid before LC-MS analysis. The quantification of acetyl-CoA was 
performed as described previously with slight modification (Snyder et al., 2015)). Briefly, 
cells were quenched with 750 μL of ice-cold 10% trichloroacetic acid (TCA) in water 
spiked with yeast extract labeled with  [13C3 15N1]-pantothenate. Samples were pulse-
sonicated for 30 s with a probe tip sonicator and centrifuged at 16,000 g for 10 min. The 
supernatants were loaded to Oasis HLB 1cc (30 mg) SPE columns (Waters) conditioned 
with 1 mL methanol. After 1 mL wash with water, the samples were eluted with 1 mL of 
25 mM ammonium acetate in methanol and dried under nitrogen. The samples were re-
suspended in 50 μL of water with 5% 5-sulfosalicylic acid. The acetyl-CoA was analyzed 
by an Ultimate 3000 autosampler coupled to a Thermo Q Exactive HF Hydro 
Quadrapole-Orbitrap Mass spectrometer as previously described (Frey et al., 2016). The 
same LC conditions and column were used as described for the organic acid analysis. 
Transmission Electron Microscopy 
Tissues for electron microscopic examination were fixed with 2.5% glutaraldehyde, 2.0% 
paraformaldehyde in 0.1M sodium cacodylate buffer, pH7.4, overnight at 4°C.   After 
subsequent buffer washes, the samples were post-fixed in 2.0% osmium tetroxide for 1 
hour at room temperature, and then washed again in buffer followed by water.  After 
dehydration through a graded ethanol series, the tissue was infiltrated and embedded 
in EMbed-812 (Electron Microscopy Sciences, Fort Washington, PA).  Thin sections were 
stained with uranyl acetate and lead citrate and examined with a JEOL 1010 electron 
microscope fitted with a Hamamatsu digital camera and AMT Advantage image capture 
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software. To quantify lipid droplets, 30-40 cells per sample group were examined in two 
separate experiments and lipid droplets were counted by eye.   
Seahorse XF Assay 
OCR and ECAR were measured using a 96-well XF extracellular flux analyzer (Seahorse 
Bioscience).  250k cells per well at 48 hours post-activation in optimal or low glucose 
IB2H medium , washed with PBS, and transferred to warm, optimal or low glucose 
supplemented, XF Seahorse medium.   
NSCLC T cell Isolation 
PBMC and TIL were isolated from NSCLC patients and extracted as described (Huang et al., 
2017). 
Statistics 
Statistical analysis was performed using a 2-tailed Student’s t-test or Mann-Whitney test 
after the analysis of distribution of variables.  In the case of multiple comparisons, one-
way ANOVA followed by Tukey LSD was performed.  Significance determined at p < 0.05, 
and error bars indicating mean plus or minus SEM.  All calculations were made using 
GraphPad Prism 5 software (GraphPad Software Inc.) or Microsoft Excel. 
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Figure 3-1:  Development and testing of IB2H media. 
A.  The first phase of generating a serum free medium that can expand all human T cell 
subsets, consisted of creating 10 prototype media by mixing different ratios of 3 base 
media that contain different concentrations of amino acids, vitamins, trace elements, 
antioxidants, metal ions, polyamines, and lipids.  These prototype media were tested for 
their ability to expand activated primary human T cells using anti-CD3/CD28 coated 
beads and reiterated with a Design of Experiments (DOE) statistical quadratic model 
through Design-Expert® 9.0.1 software with a desired response to maximally expand 
human T cells without serum supplementation.  Phase 2 consisted of eliminating 
xenogeneic components, examining metabolites consumed in serum-supplemented X-
VIVOTM-15 medium and prototype media from phase 1, and modifying media so that 
concentrations of metabolites are maintained upon feeding of activated T cells.  The 
final phase focused on optimizing carbon sources, lipid concentrations, lentiviral 
transduction efficiency, and cytokine production post-activation on activated human T 
cells.    B. Primary human T cells were stimulated with anti-CD3/CD28 coated beads and 
cultured in one of ten custom media.  Population doublings for each medium were 
normalized to the expansion obtained with X-VIVOTM 15 supplemented with 5% human 
AB serum. Data are representative from at least seven experiments.  Error bars reflect 
SEM.  These data were used for the statistical analysis to optimize cell expansion.  C. 
Contour and response surface plots for designing the optimal media for T cell expansion. 
Statistical analysis performed on StatEase Design-Expert® 9.0.1 based on a Quadratic 
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model with a desired response of maximum T cell serum-free expansion generated from 
results of prototype medias in A.  Based on this analysis, a predicted optimal medium 
mixture formulation was generated. D.  Total T cells were stimulated with anti-
CD3/CD28 coated beads in X-VIVOTM 15 supplemented with 5% human AB serum or in 
the Design of Experiments (DOE) predicted medium (A).  Data are representative of 3 
donors.  E. Total T cells were stimulated with anti-CD3/CD28 coated beads in X-VIVOTM 
15 supplemented with 5% human AB serum or in the variants of the predicted medium 
containing a range of concentrations of glucose, galactose and lipids. Data are 
representative of 5 donors. 
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Figure 3-2:  1B2H Supports and Robustly Expands Human T Cells in the Absence of 
Serum 
A-D.  Primary human CD4 and CD8 T cells were mixed at a 1:1 ratio, activated with 
CD3/28-coated beads, and cultured in (A) RPMI, (B) AIM V CTS, (C) X-VIVO 15, or (D) 
1B2H media with no serum (circles) and with serum (squares). The population doubling 
rate was measured by cell counting on the days indicated by a symbol. Error bars 
represent SEM. 
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Figure 3-3: Durable Tumor Control by CAR T Cells Expanded in the Absence of Human 
Serum 
A. NALM6 tumor cells expressing luciferase were engrafted in NSG mice, and 7 days 
later (day −1), luciferase expression was determined. Mice were then randomized into 
treatment groups and 10 million of the indicated T cells (described in Figure 3) were 
infused on day 0. Luciferase expression within each mouse was measured on days 13 
and 43 after T cell infusion.  B. Kaplan-Meier curve showing tumor-free survival of each 
of the indicated groups. C-D.  14 (C) and 40 (D) days after T cell infusion, peripheral T cell 
levels were measured using TruCount beads. Each symbol represents data collected 
from a single mouse. 
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Figure 3-4: Durable Control of Tumor Growth of Patient T Cells Expanded with 1B2H 
SFM 
A. CD19 CAR transduced T cells from Figure 5 were diluted with untransduced (UT) 
T cells so that each population contained 40% transduced T cells. These cells were then 
incubated with CD19-expressing K562 for 5 hr, and intracellular IL-2 and TNF-α were 
measured by flow cytometry. B. Summary data for 3 multiple myeloma patients from 
the data described in (A). Filled symbols represent T cells expanded in serum, and open 
symbols represent T cells expanded in the indicated media in the absence of serum. C. 
NALM6 tumor cells expressing luciferase were engrafted in NSG mice, and 7 days later 
(day −1), luciferase expression was determined. Mice were then randomized into 
treatment groups and 10 million of the indicated T cells (described in Figure 5) were 
infused on day 0. Luciferase expression within each mouse was measured on days 12 
and 62 after T cell infusion. D. Kaplan-Meier curve showing tumor-free survival (animals 
that maintained less than the 1 × 107 light units) of each of the indicated groups. 
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Figure 3-5:  Generation of a chemically defined, customizable media that can expand 
human T cell subsets in the absence of serum. 
A.  Total CD4 T cells were labeled with CFSE and activated by anti-CD3/CD28 coated 
beads in 1B2H medium containing optimal glucose, no glucose, or optimal glucose 
without glutamine. T cell proliferation was measured by CFSE dilution by flow 
cytometry. Data is representative of 3 independent experiments.  C-E.  Primary human 
CD4 T cells were sort-purified into TN (CD25-, CD45RA+, CCR7+, CD27+), TCM ((CD25-, 
CD45RO+, CCR7+, CD27+) and TEM (CD25-, CD45RO+, CCR7-, CD27-) and stimulated with 
anti-CD3/CD28 coated beads in 1B2H medium with or without 5% human serum. (See 
S2 for gating strategy).  Cell expansion was monitored by Coulter counter on the 
indicated days.  Data is representative of 2-3 donors and independent experiments.  *p 
<0.05, **p<0.01, paired two-tailed Student’s T test on day 9 population doublings.  ns = 
not significant. 
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Figure 3-6:  Gating strategy and purities for sorting human naïve, central memory, and 
effector memory CD4 T cell subsets. 
A-F. T cells for subset experiments were sorted using this gating strategy.  Human CD4 T 
cells were isolated from peripheral blood mononuclear cells (PBMC) and obtained from 
the Human Immunology Core at the University of Pennsylvania. Cells were sorted in the 
following order by FSC-A/ SSC-A gating, singlet 1 gating, singlet 2 gating, CD45RA and 
CD25 gating, and then by CCR7 and CD27.  E.  Naïve (TN) T cells were designated as cells 
that are CD45RA+, CD25-, CCR7+, CD27+.  F.  Central memory (TCM) T cells were 
designated as cells that are CD45RA-, CD25-, CCR7+, CD27+.  Effector memory (TEM) T cells 
were designated as cells that are CD45RA-, CD25-, CCR7-, CD27-.  G-I.  Sorted populations 
were immediately re-run through the sorter to measure CCR7 and CD27 expression to 
determine sorting purity.  Data is representative of dozens of sorts performed for 
publication. 
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Figure 3-7: Effector Memory T cells are resistant to glucose-mediated IFNγ 
suppression. 
   
A.  The indicated subsets were stimulated with anti-CD3/CD28 coated beads in the 
presence of optimal (35mM) or low (0.35mM) glucose.  Cell expansion was monitored 
by Coulter Counter on the indicated days. Statistics were performed on day 9 population 
doublings. B-C.  T cell subsets that were expanded for 24 hours with anti-CD3/CD28 
coated beads or expanded for 9-11 days with anti-CD3/CD28 coated beads before 
IFNγ/IL-2 production was measured after PMA/ ionomycin treatment.  D.  CCR7 and 
CD27 expression measured on T cell subsets described in A. seven days after T cell 
expansion.  E-F.  Data from B-C. are summarized from three independent experiments 
and donors (See S3 for IL-2 and TNFα quantification).  G-H.    Data from D. summarized 
from three independent experiments.  Error bars reflect SEM.  *p <0.05, **p<0.01, 
paired two-tailed Student’s T test.  ns = not significant. 
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Figure 3-8:  IL-2 and TNFα production is not significantly affected by glucose in human 
CD4 T cells. 
A.  T cell subsets were activated as described in 2C and TNFα production was measured 
9 days post-stimulation after PMA/ionomycin treatment. B-C.  Percentages of TNFα and 
IL-2+ cells were quantified from A.  D-F.  Quantification of MFI from IFNy, IL-2, TNFα 
positive cells in optimal or low glucose 9 days post-stimulation after PMA/ionomycin 
treatment.  Error bars reflect SEM.  All data is representative of 3 independent 
experiments.  *p <0.05, **p<0.01, paired two-tailed Student’s T test.  ns = not 
significant. 
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Figure 3-9:  Effector memory T cells express CD25 for a longer duration post-activation 
in limiting glucose. 
A-B.  Indicated T cell subsets were activated for 3 (A) or 7 days (B) using anti-CD3/CD28 
coated beads and CD25 expression was measured. C-D.  Percentage of CD25 high 
expressing cells on days 3 and 7 post-activation were quantified from A. and B. 
respectively.  Error bars reflect SEM.  Data are representative of 3 independent 
experiments.  *p <0.05, **p<0.01, paired two-tailed Student’s T test. 
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Figure 3-10:  Effector memory T cells are unable to augment oxidative phosphorylation 
in low glucose. 
A-B.  Total CD4 T cells were activated with anti-CD3/CD28 coated beads in optimal 
(35mM), medium (3.5mM), low (0.35mM), or no glucose (0mM) for 48 hours and basal 
extracellular acidification rate (ECAR) and basal oxygen consumption rate (OCR) were 
measured by XF Seahorse Analyzer.  C-D.  Total CD4 T cells were activated with anti-
CD3/CD28 coated beads in optimal and low glucose and pre-treated in the presence of 
etomoxir (ET) or vehicle (DMSO) for 48 hours before basal oxygen consumption rate 
(OCR) and extracellular acidification rate (ECAR) was measured by XF Seahorse Analyzer.  
E-F.  Same as A., but the indicated T cell subsets were studied. G.  Lactate was measured 
in the media of indicated T cell subsets after 24, 48, or 72 hours of culture using HPLC. 
H.  Relative intracellular abundances of lactate from sorted activated T cell subsets at 48 
hours by LC-MS, normalized by cell number and cell volume.  I-N.  Same as C and D., but 
the indicated T cell subsets were studied.  Error bars reflect SEM.  All data is 
representative of 4 independent experiments and donors. *p <0.05, **p<0.01, paired 
two-tailed Student’s T test or in case of multiple comparisons, one-way ANOVA followed 
by Tukey LSD.  ns = not significant. 
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Figure 3-11:  Effector memory T cells contain fewer lipid droplets than other T cell 
subsets at optimal glucose. 
A.  Total CD4 T cells were left unactivated or activated with anti-CD3/CD28 coated beads 
in optimal or low glucose. After 2 days of culture, T cells were examined using 
transmission electron microscopy.  Arrow indicates presence of lipid droplets.  Scale 
bars representing length of 2 microns is indicated below the panel. B. Total CD4 T cells 
were activated with anti-CD3/CD28 coated beads in optimal glucose for 48 hours and 
then transferred into medium with low glucose and cultured for up to an additional 48 
hours.  Bodipy 493/503 was used to stain the cells at the indicated time points after 
being transferred to low glucose for 0, 4, 24, or 48 hours.  Fluorescence was visualized 
via confocal microscopy, 30-40 randomly selected cells per experiment were imaged 
(See S5 for quantification). C.  Total CD4 T cells were activated with anti-CD3/CD28 
coated beads for 3 or 6 days in optimal or low glucose.  Cell lysates were probed for 
LC3B isoforms and β-actin (See S5 for quantification).  Data are representative of 3 
independent experiments and donors.  D.  T cells were stimulated with anti-CD3/CD28 
coated beads and transduced with LC3B-mcherry.  After 48 hours of activation, cells 
were stained with Bodipy 493/503 and co-localization was visualized via confocal 
microscopy. 30-40 randomly selected cells per experiment were imaged.  Data is 
representative of 3 independent experiments and donors.  E.  Indicated subsets were 
stimulated with anti-CD3/CD28 coated beads in the presence of optimal or low glucose.  
After 2 days of culture, T cells were examined using transmission electron microscopy.  
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Scale bar representing length of 2 microns is indicated below the panel.  F-G.  The 
number of lipid droplets per micrograph were quantified from approximately 40 images 
per group per experiment in two independent experiments.  Error bars reflect SEM.  *p 
<0.05, **p<0.01, one-way ANOVA followed by Tukey LSD. ns = not significant. 
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Figure 3-12:  Quantification of loss of lipid droplets and autophagy by activated T cells 
in limiting glucose.  
A. Total CD4 T cells were activated as described in Figure 4B.  Mean fluorescence 
intensity (MFI) was measured by flow cytometry. Error bars reflect SEM.  Data are 
representative of 3 independent experiments.  B.  Total CD4 T cells were activated with 
anti-CD3/CD28 coated beads and placed in optimal or low glucose.  After six days, T cells 
were examined using transmission electron microscopy.  Arrows indicate presence of 
autophagosomes.  C. Total CD4 T cells were activated with anti-CD3/CD28 coated beads 
in optimal glucose for 48 hours and then transferred into medium with low glucose or 
low glucose plus Lys05 for an additional 24 hours.  Bodipy 493/503 was used to stain the 
cells at the indicated time points after being transferred to low glucose for 0, 4, 24, or 
48 hours.  D-E.  Sorted T cells were activated with anti-CD3/CD28 coated beads for 3 or 
6 days in optimal or low glucose.  Cell lysates were probed for LC3B isoforms and β-
actin. Western data is quantified via densitometry.  F-G.  Total CD4 T cells were 
activated with anti-CD3/CD28 coated beads for 5 days in optimal or low glucose in the 
presence or absence of rapamycin.  Population doublings were quantified at day 5 post-
activation.   H.  Total CD4 T cells were activated with anti-CD3/CD28 coated beads for 9 
days in optimal or low glucose in the presence or absence of rapamycin, Lys05, or both 
rapamycin and Lys05. Data is representative of 3 independent experiments and donors.  
Error bars reflect SEM.  *p <0.05, **p<0.01, paired two-tailed Student’s T test or in case 
of multiple comparisons, one-way ANOVA followed by Tukey LSD.  ns = not significant. 
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Figure 3-13:  Intracellular abundances of acetyl-CoA and TCA intermediates in 
activated T cell subsets. 
A.  Diagram depicting glycolysis and TCA cycle. B-G.  Relative intracellular abundances of 
acetyl-CoA, citrate, malate, α-ketoglutarate (α-KG), fumurate, and succinate respectively 
from indicated subsets at 48 hours by LC-MS, normalized by cell number and cell 
volume.  Error bars reflect SEM.  All data is representative of 3-4 independent 
experiments.  *p <0.05, **p<0.01, paired two-tailed Student’s T test.  ns = not 
significant. 
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Figure 3-14:  Effector Memory T cells cannot perform reductive glutaminolysis for fatty 
acid synthesis in low glucose. 
A. Model depicting how heavy glutamine is incorporated into citrate in a M+4, M+5, or 
M+6 manner and how each of those inform how glutamine is routed intracellularly.  B-
D. Indicated T cell subsets were activated with anti-CD3/CD28 coated beads in optimal 
or low glucose supplemented with heavy glutamine for 48 hours.  Percentage of M+4, 
M+5, M+6 citrate calculated from the total intracellular citrate pool of each subset by 
LC-MS is indicated.  E-G.   Indicated T cell subsets were treated identically to B.  Graphs 
show percentage of M+5 α-ketoglutarate, M+4 malate, and M+4 oxaloacetate 
calculated from the total respective intracellular pools of each metabolite for each 
subset by LC-MS.  H-J.  Indicated T cell subsets were treated identically to B.  
Percentages of M+0, M+2, and M+4 palmitate were calculated from the total 
intracellular pool of palmitate for each subset by LC-MS.  K-L.  Indicated T cell subsets 
were treated identically to B.  Percentage of M+3 pyruvate, M+3 lactate from the total 
respective intracellular pool of each subset by LC-MS. M.  Ratios of lactate secreted and 
glucose consumed were calculated from moles of lactate secreted and moles of glucose 
consumed in supernatant of T cell subsets determined by HPLC following 48 hours post-
activation.  Error bars reflect SEM.  All data is representative of 3-4 independent 
experiments.  (See S6 for overall relative metabolite abundances of each subset.)  *p 
<0.05, **p<0.01, paired two-tailed Student’s T test.  ns = not significant. 
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Figure 3-15: Effector memory T cells are less reliant on fatty acid metabolism for 
survival and expansion in low glucose. 
A-B.  Total CD4 T cells were activated with anti-CD3/CD28 coated beads in optimal or 
low glucose in the presence of TOFA or with vehicle (DMSO) for 5 days.  Total cell 
expansion is recorded on day 5 post-activation.  C.  Indicated T cell subsets were 
activated with anti-CD3/CD28 coated beads in low glucose in the presence of TOFA or 
vehicle DMSO for 5 days.  Cell expansion is recorded on day 5 post-activation. D.  
Indicated T cell subsets were activated with anti-CD3/CD28 coated beads in optimal or 
low glucose and CD36 expression was measured at 48 hours post-activation.  E.  
Quantification of D. from three independent experiments and donors.   F.  Total CD4 T 
cells were activated with anti-CD3/CD28 beads in optimal or low glucose in media 
without any exogenous lipids (fat-free) or supplemented with exogenous lipids for 9 
days.  Cell expansion was monitored by Coulter counter on the days indicated.   G.  
Indicated T cell subsets were activated with anti-CD3/CD28 coated beads in low glucose, 
fat-free medium with or without supplementation of exogenous lipids for 5 days.  Cell 
expansion was recorded on day 5 post-activation. H.  Indicated subsets were treated 
with heavy palmitate for 24 hours.  Percentages of M+2 acetyl CoA were calculated from 
the total acetyl CoA pool by LC-MS.   I.  Indicated T cell subsets were activated with anti-
CD3/CD28 coated beads in fat-free medium in low glucose with or without exogenous 
lipids.  Live cells were identified with Live/Dead Aqua by flow cytometry on day 5 post-
activation.  J.  Quantification of live cells from H.  Error bars reflect SEM.  All data is 
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representative of 3 independent experiments.  *p <0.05, **p<0.01, paired two-tailed 
Student’s T test or in case of multiple comparisons, one-way ANOVA followed by Tukey 
LSD.  ns = not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
89 
 
 
 
 
 
 
90 
 
Figure 3-16:  Reliance on fatty acid metabolism in low glucose inhibits IFNγ 
production. 
A-C.  Indicated T cell subsets were activated with anti-CD3/CD28 coated beads in low 
glucose in the presence of vehicle (DMSO) or low dose TOFA for 5 days before IFNγ and 
IL-2 production was measured after PMA/ionomycin treatment. For optimal glucose 
data, see Figure S7. B-C.  Quantification of A. from 4 independent experiments.  D.  
Indicated T cell subsets were activated with anti CD3/CD28 coated beads in low glucose, 
in the presence of minimal, 1x, or 2x exogenous lipid concentrate in fat-free medium for 
5 days post-activation before IFNγ production was measured following PMA/ionomycin 
treatment.  E-F.  Quantification of D. from 3 independent experiments.  Error bars 
reflect SEM. *p <0.05, **p<0.01, paired two-tailed Student’s T test.  ns = not significant. 
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Figure 3-17:  Inhibition of fatty acid synthesis does not significantly affect cytokine 
production in optimal glucose. 
A.   Indicated subsets were activated as in Fig 6A and cytokine expression was measured 
after PMA/ionomycin treatment in optimal glucose.  B-C.  Data from A. quantified in 4 
independent experiments.  Error bars reflect SEM.  *p <0.05, **p<0.01, paired two-
tailed Student’s T test.  ns = not significant. 
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Figure 3-18:  Tissue-specific signals and not tumor-specific signals may regulate 
mitochondrial mass in T cells from non-small cell lung cancer patients. 
A-B.  CD4+ (A) and CD8+ (B) T cells were isolated and stained with Mitotracker Deep Red 
from the peripheral blood, adjacent lung tissue, and lung tumor tissue of non-small cell 
lung cancer patients. C-D.  Data from A-B quantified from 3 patients and 3 independent 
experiments.  E-G.    CD8+,CD45RA- T cells from the peripheral blood (E), adjacent lung 
tissue (F), and lung tumor tissue (G) were stained with Mitotracker Deep Red.   
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Figure 3-19:  Working model for subset-specific adaption to limiting glucose. 
A. When activated in sufficient glucose, naïve T cells perform glycolysis and uptake lipids 
from their environment and make a small amount of IFN-γ.  When activated in limiting 
glucose, naïve T cells increase their reliance on fatty acid oxidation, oxidative 
phosphorylation, and fatty acid synthesis.  The reliance on fatty acid synthesis inhibits 
IFN-γ production by naïve T cells.  B.  When activated in sufficient glucose, effector 
memory T cells perform glycolysis and uptake less lipids from their environment than 
naïve T cells, and make a large amount of IFN-γ.  When activated in limiting glucose, 
effector memory T cells increase their reliance on fatty acid oxidation, but do not 
increase oxidative phosphorylation or fatty acid synthesis pathways.  By not relying on 
fatty acid synthesis, effector memory T cells are able to maintain large amounts of IFN-γ 
production in limiting glucose. 
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Tables 
Table 3-1: 
A. 
Prototype Media Base 1 
Lean media with 
balanced AA and 
vitamins 
 
Base 2 
Non-essential AA, 
vitamins, trace 
elements and  proteins 
 
Base 3 
Concentrated AA, 
vitamins, trace 
elements, metal ions, 
antioxidants, 
polyamines and lipids 
 
1 1.00 0.00 0.00 
2 0.50 0.00 0.50 
3 0.50 0.50 0.00 
4 0.00 0.50 0.50 
5 0.33 0.33 0.33 
6 0.00 1.00 0.00 
7 0.00 0 1.00 
8 0.66 0.17 0.17 
9 0.17 0.17 0.66 
10 0.17 0.67 0.17 
 
B. 
X-VIVOTM 15 
Media + 5% Serum 
Day 0 
(% Remaining) 
Day 3 
(% Remaining) 
Day 3 Post-Feed 
(% Remaining) 
Day 6 
(% Remaining) 
L-Arginine 100 62 91 52 
L-Glutamine 100 58 91 28 
L-Leucine 100 69 93 64 
L-Methionine 100 62 91 52 
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L-Serine 100 7 78 nq 
L-Tryptophan 100 26 91 nq 
Ethanolamine 
HCl 
100 nq 70 nq 
 
C. 
Prototype Media Day 0 
(% Remaining) 
Day 3 
(% Remaining) 
Day 3 Post-Feed 
(% Remaining) 
Day 6 
(% Remaining) 
L-Arginine 100 78 95 76 
L-Glutamine 100 66 94 62 
L-Leucine 100 67 91 58 
L-Methionine 100 60 91 58 
L-Serine 100 nq 83 14 
L-Tryptophan 100 nq 92 nq 
Ethanolamine 
HCl 
100 48 96 40 
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Table 3-1:  Creation of prototype media and spent media analysis for development of 
1B2H medium.  
A.  Proportions of SFM1, SFM2, and SFM3 used to create ten media variants for 1B2H 
media creation are indicated.  These ten media variants were then used in Figure S1.  B.  
Total T cells were activated with anti CD3/CD28 coated beads in XVIVOTM-15 media 
supplemented with 5% human serum.  Relative amounts of amino acids were analyzed 
at indicated time points by HPLC.  Cells were counted on Day 3, and every other day 
afterward so that new media could be added to keep the concentration of cells at 500k 
cells/mL. nq = below limit of detection, not quantifiable.  C.  Total T cells were activated 
with anti-CD3/CD28 coated beads in 1B2H media.  Relative amounts of amino acids 
were analyzed at indicated time points by HPLC.  Cells were counted on Day 3, and every 
other day afterward so that new media could be added to keep the concentration of 
cells at 500k cells/mL. nq = below limit of detection, not quantifiable.  
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Table 3-2: 
Glucose 
Concentration 
(mM) 
Day 0 
(% 
Remaining) 
Day 3 
(% 
Remaining) 
Day 5 
(% 
Remaining) 
Day 7 
(% 
Remaining) 
Day 9 
(% 
Remaining) 
35.0 100 82.72727 68.78788 69.39394 72.72727 
24.5 100 74.65619 55.59921 54.6169 38.25137 
17.5 100 67.75956 36.61202 38.79781 29.46955 
10.5 100 49.76744 1.395349 nq nq 
7.0 100 31.46853 nq nq nq 
3.5 100 9.859155 nq nq nq 
0 nq nq nq nq nq 
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Table 3-2:  Determination of the optimal glucose concentration in 1B2H media.  
Total T cells were activated with anti-CD3/CD28 coated beads in 1B2H media 
supplemented with the indicated amounts of glucose.  Relative amounts of glucose 
remaining in the media were determined at the indicated time points by HPLC. Cells 
were counted on Day 3, and every other day afterward so that new media could be 
added to keep the concentration of cells at 500k cells/mL.  nq= below limit of detection, 
not quantifiable 
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Table 3-3: 
A. 
Metabolites 
consumed  
TN  
Optimal 
(mg/L) 
TN Low 
(mg/L) 
TCM 
Optimal 
(mg/L) 
TCM Low 
(mg/L) 
TEM 
Optimal 
(mg/L) 
TEM Low 
(mg/L) 
Glucose 10785.74+/
-1326.96 
237.85+/-
64.74 
9257.99+/-
1177.92 
237.89+/-
64.75 
6333.86+/-
607.04 
78.28+/-
21.31 
L-Glutamine 288.31+/-
17.49 
278.38+/-
13.77 
270.38+/-
9.02 
264.85+/-
7.86 
260.23+/-
13.89 
272.65+/-
17.42   
L-Serine 26.45+/-
3.59 
14.70+/-
4.58 
24.15+/-
1.79 
11.77+/-
1.71 
15.74+/-
0.60 
9.98+/-
1.19 
L-Lysine HCl 16.14+/-
1.42 
6.25+/-
1.80 
17.61+/-
1.72 
4.93+/-
1.62 
12.75+/-
1.53 
5.91+/-
1.71 
L-Arginine 13.96+/-
4.03 
6.98+/-
2.02 
12.64+/-
0.59 
5.23+/-
1.51 
9.54+/-
1.14 
6.81+/-
1.97 
L-Isoleucine 9.60+/-
2.77 
5.64+/-
1.63 
9.95+/-
0.78 
4.71+/-
2.33 
7.85+/-
0.89 
5.31+/-
1.53 
L-Leucine 8.23+/-
3.20 
6.20+/-
1.79 
14.08+/-
3.96 
5.53+/-
1.60 
10.23+/-
2.96 
5.97+/-
1.72 
L-Valine 8.28+/-
2.36 
3.92+/-
1.14 
9.09+/-
2.59 
3.28+/-
0.95 
6.71+/-
1.92 
3.79+/-
1.10 
L-Tyrosine 5.28+/-
1.52 
2.29+/-
0.66 
5.51+/-
1.52 
1.54+/-
0.44 
4.04+/-
1.15 
2.04+/-
0.59 
L-Methionine 4.07+/-
0.94 
3.35+/-
0.97 
5.46+/-
0.17 
3.14+/-
0.91 
3.94+/-
0.72 
3.08+/-
0.11 
L-Tryptophan 3.76+/-
1.08 
2.87+/-
0.83 
3.32+/-
0.91 
2.33+/-
0.67 
2.70+/-
0.74 
2.94+/-
0.85 
L-
Phenylalanine 3.24+/-
1.91 3.06+/1.22 
6.92+/-
1.91 
2.54+/-
1.12 
4.90+/-
1.35 
3.12+/-
1.36 
 
B. 
Metabolites 
Produced 
TN 
Optimal 
(mg/L) 
TN Low 
(mg/L) 
TCM 
Optimal 
(mg/L) 
TCM Low 
(mg/L) 
TEM 
Optimal 
(mg/L) 
TEM Low 
(mg/L) 
Lactate 12271.47+
/-1471.81 
587.28+/-
41.94 
9826.15+/-
684.33 
629.17+/-
39.20 
6373.29+/
-377.56 
616.05+/-
61.78 
Ammonia 25.43+/-
6.14 
34.52+/-
7.57 
24.14+/-
6.46 
33.08+/-
9.39 
22.61+/-
6.37 
28.77+/-
7.13 
L-Glutamic Acid 11.83+/-
2.66 
11.44+/-
2.92 6.71+/-0.90 
6.96+/-
1.88 
7.40+/-
1.18 
2.52+/-
0.82 
103 
 
L-Alanine 1.17+/-
0.51 
8.43+/-
1.56 1.84+/-1.01 
8.55+/-
2.31 
1.50+/-
0.42 
3.65+/-
1.37 
L-Aspartic Acid nq 4.51+-
/1.49 
nq 2.81+/-
1.54 
nq 2.51+/-
1.96 
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Table 3-3:  Production and consumption of metabolites by activated T cell subsets.  
Indicated T cell subsets were activated with anti-CD3/CD28 coated beads for 48 hours.  
A.  Rates of consumption of selected amino acids and organic acids were determined by 
HPLC of supernatant and comparing that to un-used respective media kept at cell 
culture conditions for 48 hours.  B.  Rates of production of selected amino acids and 
organic acids were determined by HPLC of supernatant and comparing that to un-used 
respective media kept at cell culture conditions for 48 hours. nq= below limit of 
detection, not quantifiable. Rates of production are +/- SEM. 
 
105 
 
Chapter 4- Understanding mitochondrial remodeling during T cell 
activation 
 
Introduction 
 
 T cells undergo significant mitochondria biogenesis upon T cell activation and 
upregulate mitochondrial function (Ron-Harel et al., 2016).  Researchers have observed 
increases in numerous mitochondrial pathways including oxidative phosphorylation, 
fatty acid metabolism, and one-carbon metabolism upon activation (Procaccini et al., 
2016).  Oxidative phosphorylation and electron transport are essential for proliferation 
following TCR stimulation, while fatty acid and one-carbon metabolism can generate the 
necessary building blocks for proliferating cells. Furthermore the mitochondrion 
generates reactive oxygen species that are vital for nuclear factor of activated T cells 
(NFAT), translocation into the nucleus and IL-2 production during T cell activation 
(Chang et al., 2013; Sena et al., 2013).  Thus mitochondria are critical for T cell 
proliferation and serve necessary functions well beyond energy production.  
It is widely believed that mitochondrial shape and cristae structure are 
inherently tied to mitochondrial function (Cogliati et al., 2013; Paumard et al., 2002).  
Although most of this evidence was obtained during the context of apoptosis induction 
or in Opa1 knockout cells.  During T cell activation, mitochondria begin to loosen their 
mitochondrial cristae and begin increasing rates of mitochondrial fission (Buck et al., 
2016).  It remains unknown which activation signals initiate mitochondrial morphology 
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changes, and what effects those morphology changes have on respiration and other 
mitochondrial functions. 
We sought to identify the activation signals responsible for mitochondrial 
morphology changes, and how those changes affected cellular respiration and ROS 
production.  We found that human CD4 T cells significantly and reversibly alter 
mitochondrial structure upon activation.  Mitochondria undergo dramatic swelling and 
cristae disruption that is glucose and mammalian target of rapamycin complex 1 
(mTORC1) dependent.  Swelling and cristae disruption were strongly correlated, and 
were reversed as cells rest down or more quickly when cells were transferred to limiting 
glucose.  We also observe that cytochrome C, an essential component of the electron 
transport chain and pro-apoptotic protein, is cytoplasmic in T cells activated in abundant 
glucose, but can readily sequester cytochrome C in the mitochondria if those cells are 
transferred to low glucose environments.  By utilizing multiple pharmacological 
inhibitors/nutrient conditions, we found that cristae disturbance strongly correlated to 
rates of glycolysis, reactive oxygen species production, and voltage potential.  From this 
data we have generated a model that proposes glucose uptake and mTORC1 signaling 
are required to induce an activation signal that induces mitochondrial swelling and 
cristae disruption.  We speculate that the cristae disturbance and mitochondrial swelling 
drive ROS production, which is known to be required for optimal T cell proliferation.  
When mitochondria are unable to restore structure, ROS production remains elevated, T 
cells are able to exhibit increased proliferation but at cost of increased death.   When 
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mitochondria are not able to alter mitochondrial structure, they are unable to produce 
ROS and generate appropriate proliferation signals. Taken together, we propose 
Warburg metabolism promotes cellular division by a novel mechanism of altering 
mitochondrial structure and ROS production. 
Results 
CD4 T cells reversibly alter mitochondrial structure upon activation in a glucose 
dependent manner 
 Numerous reports have also linked nutrient availability to mitochondrial 
structure (Liesa and Shirihai, 2013; Mishra and Chan, 2016).  We first noticed large 
mitochondrial structure differences during CD4 T cell activation when cells were grown 
in optimal (35mM) or low (0.35mM) glucose in previous work done by our laboratory 
(Ecker et al., 2018). To better understand how human CD4 T cells altered mitochondria 
structure upon stimulation, we kinetically examined how mitochondria cristae, 
mitochondrial area, and shape changed in CD4 T cells grown in optimal and low glucose 
using anti-CD3/CD28 coated beads.  We found that cells grown in optimal glucose had 
large changes to mitochondrial cristae.  Mitochondrial cristae lost strict, parallel 
patterning, became less frequent in number, and even became circular structures within 
the mitochondria themselves in a term we call “cristae disturbance”.  We quantified 
cristae disturbance using a scale ranging from 1 to 5 (Fig 4-1).  A numerical value of 1 
represents “normal mitochondria” with tight, parallel, abundant cristae, while 5 
represents the “most disturbed” mitochondria  with loose, few and erratic patterning of 
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cristae.   We observed that cells experienced maximal disturbance by day 2 post-
activation, and slowly restored mitochondrial shape as cells began to rest (Fig 4-2 A,B).   
This followed a similar kinetic pattern in cells grown in low glucose, although the 
magnitude of disruption was decreased.  Individual mitochondrial area drastically 
increased following near identical kinetics to cristae disruption, again with low glucose 
experiencing less dramatic swelling (Fig 4-2 C).  As mitochondria swelling increased, 
mitochondria became less elongated (Fig 4-2 D).  All of this was largely temporary, and 
as cells began to slow rates of proliferation their mitochondria cristae, size, and shape 
began to normalize to baseline.  Interestingly, the mitochondria of cells in low glucose 
began to elongate even further than baseline by day 5 post-activation.  Fascinatingly 
despite the loss in both cristae structure and patterning, T cells experience large 
increases in oxygen consumption rate (OCR, an indirect measurement of oxidative 
phosphorylation) by 24 hours post-activation, maintain the ability for heightened 
oxidative phosphorylation, and begin to slowly decrease oxidative phosphorylation back 
down to baseline (Fig 4-2 E).  Extracellular acidification rate (ECAR, an indirect 
measurement of glycolysis) increases until 48 hours post-activation, before slowly 
decreasing (Fig 4-2 F).  ECAR was not observed to decrease entirely back to baseline by 
10 days post-activation.   
 While cells were able to restore mitochondrial size and cristae structure several 
days following activation, it was unclear whether individual mitochondria would be able 
to recover, or whether the swollen mitochondria were removed by mitophagy and new 
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mitochondrial were generated.  We activated T cells in optimal glucose until maximal 
cristae disturbance was observed (48 hours post activation) and switched some of the 
cells acutely to low glucose media for several hours (Fig 4-3 A).   We found that within 1 
hour, the mitochondria from cells moved from optimal glucose to low glucose, were 
indistinguishable in cristae disturbance or size from mitochondria grown in low glucose 
the entire duration of activation (Fig 4-3 B-D).  This data suggests that mitochondria are 
able to adapt readily to nutrient alterations by quickly altering their native cristae 
morphology and size. 
 
Cytochrome C is not sequestered in the mitochondria of activated T cells in optimal 
glucose 
Mitochondrial swelling often occurs from a large influx of water and solutes from 
the cytoplasm and frequently associated with induction of intrinsic apoptosis pathways 
(Cai et al., 1998; Crompton, 1999).  The mitochondria permeability transition pore 
(MPTP) forms a pore connecting the inner and outer mitochondrial membranes and 
regulates the permeability of the mitochondria.  The individual components of the 
MPTP have been frequently debated and highly controversial, but can permit the 
release of cytochrome C from the mitochondria (Gogvadze et al., 2006).  Cytochrome C 
is a highly soluble protein typically involved in the electron transport chain, and can be 
released from the mitochondria and initiate apoptosis under certain stimuli.  Despite 
seeing very little cell death and no observable caspase cleavage upon T cell activation at 
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48 hours post-activation during maximal mitochondrial swelling, we sought to examine 
if the MPTP was indeed opening upon activation. 
 We first transduced CD4+ T cells with a lentiviral construct expressing 
cytochrome C fused to GFP.  We found that T cells grown in optimal glucose expressed 
cytochrome C throughout the cytoplasm and nucleus (Fig 4-4 A).  However as we placed 
cells into low glucose, we found that cytochrome C began accumulating in distinct 
cytoplasmic punctae.  We later verified that these cytoplasmic punctae were indeed 
mitochondria.  This process took up to 48 hours-post activation for complete loss of 
nuclear fluorescence.  Lentiviral overexpression and fusion protein dynamics can 
interfere with proper localization of expressed proteins, and subsequently used cellular 
fractionation to confirm cytochrome C localization in wild-type activated T cells.  Once 
again we found that cytochrome C largely did not localize to the membrane fraction 
(which includes endoplasmic reticulum, golgi apparatus, mitochondria contents) in T 
cells activated in optimal glucose (Fig 4-4 B).  Whereas T cells stimulated in low glucose 
localized cytochrome C entirely to the membrane fraction.  Again matching similar 
kinetics, when cells are moved from optimal to low glucose, cytochrome C levels in the 
cytoplasmic over the next 48 hours are slowly decreased (Fig 4-4 C).  This process 
appears to be unique to T cells, because embryonic kidney 293T cells do not have 
cytoplasmic cytochrome C in optimal glucose.   
 
Mitochondrial dysfunction correlates to glycolytic rate and not oxidative phosphorylation 
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 Several studies have reported that common pharmacological drugs/nutrient 
conditions can have a range of effects on mitochondrial shape or fusion/fission 
dynamics in different cell types (Buck et al., 2016; Liesa and Shirihai, 2013; Mishra and 
Chan, 2016; Trudeau et al., 2012).  We found that CD4 T cells activated in hypoxia or 
Mdivi1 (a mitochondrial fusion inhibitor) had significantly higher cristae disturbance at 
day 5 post-activation than cells simply activated in optimal glucose (Fig 4-5 A,B).   
Furthermore, we found that cells grown in rapamycin (an mTORC1 inhibitor) had 
reduced levels of cristae disturbance compared to cells in optimal glucose.  This directly 
correlated to their basal glycolytic rates as measured by the extracellular acidification 
rate (ECAR, Fig 4-5 C,E).   Surprisingly mitochondrial cristae disruption had no significant 
correlation to basal rates of oxidative phosphorylation as measured by oxygen 
consumption rate (OCR, Fig 4-5 D).   
Mitochondrial dysfunction correlates to ROS production and voltage potential 
We started to ask if these mitochondrial morphology changes could affect other 
mitochondrial functions or products.  We found that the most swollen and disturbed 
mitochondria also generated the highest levels of ROS and voltage potential (Mdivi1 or 
hypoxia), whereas the cells with the least disruption had the least ROS or voltage 
potential (low glucose or rapamycin treatment, Fig 4-6 A-B). While our data currently 
indicates correlations, we hypothesize that these mitochondrial morphology changes 
are causing the increase in ROS production following activation. 
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Future Directions and Discussion 
Our data supports a model where an activation signal drives mitochondrial 
morphology changes, which subsequently drives ROS production.  With the recent data 
that reactive oxygen species facilitates tumor and T cell proliferation, we hypothesize 
ROS are needed at a careful balance in T cells (Kong and Chandel, 2018; Sena et al., 
2013).  Too little ROS, and T cells may not be able to make the important proliferative 
signals (IL-2 production, NFAT nuclear localization, ERK MAPK or JNK pathway activation) 
needed to support proliferation, while too much ROS can cause excessive cellular 
damage and death (Fig 4-7).  Much of our current work is focused on altering ROS in 
settings of cristae disturbance and examining effects on cellular viability and 
proliferation.  We have developed two lentiviral constructs that overexpress a 
mitochondria-targeted catalase and superoxide dismutase, two enzymes with 
antioxidant activity. 
We are also attempting to identify the “activation signal” responsible for these 
mitochondrial morphology changes.  We are attempting to create a minimalist system 
where we isolate mitochondria and test the identity of the “signal” by solely adding 
activation signals, activated T cell cytoplasm, or glucose to induce morphology changes.  
The process is incredibly slow because our only method of examining cristae is through 
low-throughput, expensive electron microscopy.  However most of our experiments 
have indicated mitochondrial size and cristae disturbance are strongly related, and we 
may be able speed these up in confocal experiments by examining isolating and 
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quantifying individual mitochondrial size.  One of the other major concerns is that if this 
“signal” is needed for other parts of T cell activation, it may be hard to exclusively 
examine its role in mitochondrial morphology. 
Our data that cytochrome C is not sequestered in the mitochondria is particularly 
surprising, considering its role in apoptosis. Identifying the maturation state of 
cytochrome C may also play a large role in better understanding of this process.   We 
will need increased resolution using inducible cytochrome C expression and/or 
translation inhibitors to fully identify cytochrome C kinetics, maturity and localization 
status.  Formation of mature cytochrome C (holocytochrome C) requires mitochondrial 
localization and its release is sufficient to induce apoptosis (Cai et al., 1998). The 
precursor apocytochrome C travels to the mitochondria and can spontaneously insert 
into the mitochondrial outer membrane, and is not able to induce apoptosis.  
Apocytochrome C eventually binds to heme lyase where it becomes fully matured 
bearing a heme group and refolded and traveling to the mitochondrial inner membrane.  
We cannot conclude from our current data whether holocytochrome C is leaving the 
mitochondria upon activation due to the opening of the MPTP, or whether newly made 
apocytochrome C cannot somehow enter the mitochondria in optimal glucose.  If the 
former is true, we must seek to understand why mature, cytoplasmic C is not able to 
induce caspase activation in activated T cells.  If the latter is true, it may explain why the 
cells are not inducing apoptosis but does not explain why apocytochrome C cannot 
enter the mitochondria. 
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Our data provides another example of the importance of mitochondria outside 
of oxidative phosphorylation and energy production.  This project further underscores 
an important theme throughout my thesis the surprising roles certain metabolic 
pathways or metabolic byproducts (in this case ROS) play during T cell activation and act 
on proliferative signals or production of a specific cytokine (in this study IL-2).   
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Materials and Methods 
Study Design 
The purpose of this study was to identify how mitochondria are functionally affected 
from the mitochondrial swelling and cristae disturbance observed following T cell 
activation.  The number of replicates per experiment are indicated in the figure legends 
and performed in a controlled and non-blinded manner.   
Cell Culture and Activation 
Human CD4 T cells are isolated, washed twice in PBS, and then placed in IB2H serum-
free medium containing optimal (35mM) low (0.35mM) glucose concentrations.   The 
medium was supplemented with 1x chemically defined lipid mixture (ThermoFisher 
Scientific, 11905031, individual lipid concentrations available online) and 8mM L-
glutamine.   Cells were then activated at 1 million cells per mL using Dynabeads® Human 
T-Expander CD3/CD28 (ThermoFisher Scientific, 11131D) at a concentration of 3 beads 
per cell.  Additional volumes of medium were added on Day 3 and every other day after 
so that each culture was at 0.5 million cells/mL after feeding.  Cells were treated with 
vehicle (DMSO), rapamycin (500nM, Sigma Aldrich, 553210), mdivi1 (20μM, Sigma 
Aldrich, M0199), or placed in hypoxia (1% oxygen) or normoxia (21% oxygen).     cDNA 
encoding cytochrome C-GFP was synthesized (IDT) and transferred into pTRPE, a 
lentiviral transfer vector (Leibman et al, submitted).  Lentiviral supernatants and T cell 
transduction were generated and performed as previously described (Parry et al., 2003) 
Western Blotting 
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Cells were fractionated using the Subcellular Protein Fractionation Kit for Cultured Cells 
(Thermofisher Scientific, 78840) according to manufacturer’s instructions.  Proteins 
were resolved by SDS-PAGE and transferred to nitrocellulose.  Blots were probed with 
anti-Cytochrome c (Cell Signaling Technology, 11940), HSP90 (Cell Signaling Technology, 
4877S), SDHA (Cell Signaling Technology, 11998), COX IV (Cell Signaling Technology, 
4850) 
anti-LC3B (Cell Signaling Technology, 3868) and anti-β-actin (Cell Signaling Technology, 
4970). Protein was visualized using Odyssey CLx LI-COR instrument.   
Confocal Microscopy 
To quantify neutral lipid droplets, cells were stained with 500ng/mL Bodipy 493/503 
(ThermoFisher Scientific, D3922) in serum free medium at 37 degrees Celsius for 30 
minutes.  Cells were then washed 2x with PBS and placed in their respective media.  
Cells were live imaged at 37 degrees Celsius using a stage heater on the Leica TCS SP8 
Confocal microscope.  
Mitochondrial Dyes 
Mitochondrial mass was observed by staining cells using Mitotracker Deep Red 
(Thermofisher Scientific, M22426) at 5nM for 15 minutes at 37 degrees Celsius in serum-
free media.  Mitochondrial super oxide production was quantified by staining cells using 
Mitosox Red Mitochondrial Superoxide Indicator (Thermofisher Scientific, M36008) at 
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5μM for 15 minutes at 37 degrees Celsius in serum-free media.  Voltage potential was 
quantified by staining cells using Tetramethylrhodamine, ethyl ester perchlorate (TMRE, 
Thermofisher Scientific, T669) a 20nM for 15 minutes at 37 degrees Celsius in serum-free media.  
All stained cells were washed 1-2x with PBS before confocal microscopy or flow cytometry. 
Transmission Electron Microscopy 
Tissues for electron microscopic examination were fixed with 2.5% glutaraldehyde, 2.0% 
paraformaldehyde in 0.1M sodium cacodylate buffer, pH7.4, overnight at 4°C.   After 
subsequent buffer washes, the samples were post-fixed in 2.0% osmium tetroxide for 1 
hour at room temperature, and then washed again in buffer followed by water.  After 
dehydration through a graded ethanol series, the tissue was infiltrated and embedded 
in EMbed-812 (Electron Microscopy Sciences, Fort Washington, PA).  Thin sections were 
stained with uranyl acetate and lead citrate and examined with a JEOL 1010 electron 
microscope fitted with a Hamamatsu digital camera and AMT Advantage image capture 
software.   
Seahorse XF Assay 
OCR and ECAR were measured using a 96-well XF extracellular flux analyzer (Seahorse 
Bioscience).  250k cells per well at 48 hours post-activation in optimal or low glucose 
IB2H medium , washed with PBS, and transferred to warm, optimal or low glucose 
supplemented, XF Seahorse medium.   
Statistics 
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Statistical analysis on correlational data was performed using linear regression analysis. 
Significance determined at p < 0.05, and error bars indicating mean plus or minus SEM.  
All calculations were made using GraphPad Prism 5 software (GraphPad Software Inc.) 
or Microsoft Excel. 
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Figures 
 
 
 
 
 
 
 
 
 
 
120 
 
Figure 4-1: Quantitative Scale of Cristae Disturbance. 
Representation of mitochondria with range of cristae disturbance observed in T cells 
during activation.  Scale is a numerical range from 1 to 5.  1 represents normal 
mitochondria with tight, parallel cristae morphology, while 5 represents disturbed 
mitochondria with few, loose, non-parallel cristae.   
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Figure 4-2: CD4 T cells reversibly alter mitochondrial structure upon activation in a 
glucose dependent manner. 
A.  Total CD4 T cells are activated with anti-CD3/CD28 coated beads in optimal (35mM) 
or low glucose (0.35mM) and cultured for 9 days.  Cells are fixed on days 1, 2, 5, 7, and 9 
days- post-activation for transmission electron microscopy (TEM).  Representative 
images are shown.  B.  Cristae disturbance was measured via TEM Approximately 40 
cells were measured per indicated time point and condition.  C.  Mitochondrial area was 
measured via TEM.  Approximately 40 mitochondria, and at least 20 cells were 
measured per indicated time point and condition.  D.  The maximal length of each 
mitochondria was determined and ratioed to the minimal length of each mitochondria 
via TEM.  Approximately 40 mitochondria, and at least 20 cells were measured per 
indicated time point and condition.  Error bars represent SEM. 
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Figure 4-3:  CD4 T cells adjust mitochondrial structure acutely to changes in glucose 
availability. 
A.  Total CD4 T cells are activated with anti-CD3/CD28 coated beads and grown in 
optimal or low glucose for 48 hours, or moved from optimal to low glucose for 1 or 24 
hours at 48 hours post-activation.  Representative images are shown.  B.  Cristae 
disturbance was measured via TEM (scale 1-5, 1 represents normal, parallelel, tight 
cristae morphology, while 5 represents few, loose, non-parallel cristae).  Approximately 
40 cells were measured per indicated time point and condition.  C.  Mitochondrial area 
was measured via TEM.  Approximately 40 mitochondria, and at least 20 cells were 
measured per indicated time point and condition.  D.  The maximal length of each 
mitochondria was determined and ratioed to the minimal length of each mitochondria 
via TEM.  Approximately 40 mitochondria, and at least 20 cells were measured per 
indicated time point and condition.  Error bars represent SEM. 
 
 
 
 
 
 
 
 
125 
 
 
 
 
 
126 
 
Figure 4-4: Cytochrome C is not sequestered in the mitochondria of activated T cells in 
optimal glucose. 
 
A. Total CD4 T cells were stimulated with anti-CD3/CD28 coated beads and transduced with 
cytochrome C-GFP (green) in optimal glucose. After 72 hours of activation, cells were left in 
optimal or transferred into low glucose for the indicated time points.  The right column are cells 
transduced with cytochrome C-GFP (green) and co-stained with mitotracker Deep Red (red) in 
the indicated conditions.  B.  Total CD4 T cells were activated with anti-CD3/CD28 coated beads 
in optimal or low glucose for 72 hours. Cell were fractionated into cytoplasmic and membrane 
fractions, and these fractions were probed for Cytochrome C, HSP90, SDHA, and COX.   C.  T cells 
were activated with anti-CD3/CD28 coated beads in optimal or low glucose for 72 hours, or 
moved from optimal to low glucose in the indicated time point.  Cell lysates from these T cell 
conditions or 293T cells were fractionated into cytoplasmic fractions and probed for cytochrome 
C and HSP90. 
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Figure 4-5:  Mitochondrial dysfunction correlates to glycolytic rate and not oxidative 
phosphorylation. 
A.  Total CD4 T cells are activated with anti-CD3/CD28 coated beads and grown in 
optimal glucose or during the indicated condition in optimal glucose for 5 days.  
Representative images are shown. B.   Cristae disturbance was measured via TEM (scale 
1-5, 1 represents normal, parallel, tight cristae morphology, while 5 represents few, 
loose, non-parallel cristae).  Approximately 40 cells were measured per indicated time 
point and condition.  C-E.  Total CD4 T cells are activated with anti-CD3/CD28 coated 
beads and grown in optimal or during the indicated condition for 5 days.  Basal 
extracellular acidification rate (ECAR) and basal oxygen consumption rate (OCR) were measured 
by XF Seahorse Analyzer.  For correlation analyses, linear regression analysis was used. A p-value 
of <0.05 was considered significant. 
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Figure 4-6:  Mitochondrial dysfunction correlates to mitochondrial ROS production and 
polarization. 
A-B.  Total CD4 T cells are activated with anti-CD3/CD28 coated beads and grown in 
optimal glucose, low glucose or the indicated condition in optimal glucose for 5 days 
and stained with Mitosox (A) or TMRE (B). 
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Figure 4-7:  Working model for cellular outcomes of mitochondrial disturbance. 
When T cells are activated in sufficient nutrients, an activation signal triggers 
mitochondrial swelling and cristae disturbance.  These morphological changes are 
temporary and reverse over the course of T cell activation.  Temporary swelling of 
mitochondria promotes moderate mitochondrial ROS production, and subsequently 
facilitates cellular signals (IL-2, NFAT nuclear localization, JNK, ERK MAPK pathways) that 
promote proliferation.  If the mitochondria swelling is prolonged (as in the case of 
hypoxia or Mdivi1 treatment), these mitochondria make significant amounts of ROS.  
Too much ROS promotes cellular damage and eventual cell death in these cells.  If the 
mitochondria swelling is largely prevented (as in the case of low glucose or rapamycin 
production), ROS production is minimal.  Without ROS production, proliferation is 
inhibited.  
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Chapter 5- Summary, Discussion, and Future Directions 
 
 The full implications of Warburg metabolism during T cell activation are 
numerous, complex, and still not fully understood.  Warburg metabolism endows T cells 
with the ability to not only rapidly proliferate but also to engage effector functions upon 
T cell stimulation. The tumor microenvironment presents a major challenge to T cell 
activation by restricting glucose availability. How do T cells and tumor cells, which both 
rely on Warburg metabolism, compete in the solid tumor microenvironment?   My first 
project sought to understand how T cells relied on mitochondrial pathways when they 
could no longer rely on Warburg metabolism because nutrients were limiting.    
Specifically we asked what metabolic pathways do T cells rely on when glucose is absent 
or limiting, and how does T cell reliance on alternative metabolic pathways interplay 
with their proliferation and functionality.  My second project identified a novel 
relationship between Warburg metabolism and mitochondrial structural changes during 
T cell activation.  We attempted to identify the activation signals responsible for these 
structural changes, as well as how these mitochondrial changes may subsequently 
promote T cell activation.   Collectively my thesis projects have sought to understand 
how mitochondria adapt to glucose availability to fulfill the requirements of T cell 
activation.  My thesis has identified novel connections between Warburg metabolism 
and mitochondrial pathways, and how together they contribute to T cell functionality in 
diverse environments.   
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Summary, Discussion, and Future Directions for Chapter 3 
Recent clinical trials focused on augmenting T cell responses through adoptive 
transfer of tumor-specific T cells have had breakthrough successes in treatment of 
leukemia and lymphomas. However, these therapies have failed to be effective in many 
solid tumors, where cancer cells can set up an immunosuppressive niche.  We speculate 
that these failures in solid tumors are caused by the tumor microenvironment’s limiting 
supply of key nutrients critical for T cell activation.  The existing literature that has 
explored nutrient limitation has focused on the total population of T cells found in the 
blood. We hypothesized that due to more frequent exposure to nutrient limitation, 
effector memory T (TEM) cells may be more adept at maintaining proliferative and 
functional capacity during nutrient deprivation than naïve or central memory T cells. We 
found that during glucose limitation, TN and TCM cells begin to rely on mitochondrial 
pathways.  TN and TCM cells upregulate oxidative phosphorylation by utilizing fatty acid 
oxidation and rerouting glutamine for de novo fatty acid synthesis.  Conversely, TEM cells 
are unable to increase oxidative phosphorylation or fatty acid synthesis.   We then 
discovered a surprising regulatory role for fatty acid synthesis on effector functions.  TN 
cells which relied heavily on fatty acid synthesis for survival and proliferation 
downregulated IFN-γ production during glucose depletion, while TEM cells preserved IFN-
γ production in glucose depletion by not relying on fatty acid synthesis.  
Pharmacological inhibition of fatty acid synthesis was sufficient to promote IFN-y 
production only in TN cells.  We hypothesize this independence from fatty acid synthesis 
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in TEM cells allows them to maintain functionality in all sites of nutrient limitation 
(commonly observed in inflammation or cancer).  More broadly our study uncovered a 
novel role for metabolic salvage pathways in cytokine production.  We discovered that 
alternative metabolic pathways are not simply used for survival during nutrient stress, 
but can also regulate cellular functionality by modifying cytokine production. 
 Whether TEM cells completely unable to rely on fatty acid synthesis remains 
unclear.   While TEM may not rely on fatty acid synthesis during glucose limitation, they 
can survive in fatty acid-free media for longer than TN or TCM cells.  Thus we wondered 
whether TEM cells might have been able to perform fatty acid synthesis in fatty-acid free 
media, or that they might need less fatty acids to survive.  TEM  cells might simply require 
lower amounts of fatty acids (from fatty acid synthesis and exogenous fatty acids), 
because they proliferate less than TN or TCM cells and thus may require fewer membrane 
components.  In our hands, several enzymes (ACC1, FAS) in the fatty acid synthesis 
pathway exhibit equivalent gene expression in TEM as their TN or TCM counterparts.  
However, we have not examined the RNA expression of every enzyme involved in fatty 
acid synthesis nor have we quantified protein expression of these enzymes.  We also 
would need to perform more tracing studies of glutamine and glucose to fully examine if 
TEM under certain contexts can perform fatty acid synthesis and reductive 
glutaminolysis.  Furthermore manipulation of fatty acid pathways appear tightly 
regulated and feature redundant pathways.  We had little success studying the role of 
fatty acid pathways in T cells by overexpressing known fatty acid transporters (CD36, 
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FABP4, FABP5).  While we were able to achieve surface overexpression of these fatty 
acid transporters, we never observed an increase in fatty acid uptake (data not shown).   
Our data indicate that while lipid metabolism may promote survival during 
nutrient depletion, they may frequently hamper T cell function.  However, more work 
will be needed to clarify the role of fatty acid metabolism in T cell function in vivo.  
Several solid tumors (like ovarian cancer) can form in adipose rich tissue and could be a 
useful model to better understand fatty acid metabolism during nutrient deprivation.  
Future studies may help elucidate the spatial organization of immune cells, adipocytes, 
and tumor cells in human clinical samples.    Unpublished, but publically presented work 
by Susan Kaech’s group has demonstrated that CD36 knockout, tumor-specific T cells 
have enhanced anti-tumor efficacy compared to wild-type T cells in multiple models of 
solid tumors.  This is largely consistent with our in vitro findings that exogenous fatty 
acids inhibit T cell functionality.  Further evidence of the importance of lipid metabolism 
in nutrient deprived T cells comes from a paper demonstrating TILS (tumor infiltrating 
lymphocytes) in a mouse model of melanoma had large increases in lipid uptake 
compared to T cells in the spleen (Zhang et al., 2017).  The authors found that utilizing 
peroxisome proliferator activated receptor-α (PPAR-α) agonist that promoted fatty acid 
catabolism and simultaneously promoted higher T cell engraftment and 
polyfunctionality. Interestingly, suppressing fatty acid catabolism by knocking out PPAR-
α inhibited anti-tumor functionality of T cells.  While this study appears opposed to both 
ours and Susan Kaech’s data, it could be that a careful balance of fatty acid metabolism 
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is needed for survival of T cells in the solid tumor microenvironment, while too much 
reliance on fatty acid metabolism can harm functionality. Alternatively, it may be that 
altering exogenous fatty acid uptake, and fatty acid oxidation pathways are not 
synonymous processes.  Long-chain fatty acids can have a diverse range of fates 
including components of phospholipid bilayers which all membranes are made of in the 
cell, secondary signaling messengers (which are known to play key roles in early T cell 
signaling), TCA cycle intermediates and energy.  Thus increasing fatty acid uptake may 
serve a large number of cellular processes, while fatty acid oxidation may only increase 
TCA cycle intermediate concentrations and energy production.   
 The role of fatty acids in immunity may not be entirely surprising, as links 
between fat metabolism and immunity have been evolutionarily conserved since at 
least invertebrates.  The fat bodies in insects act as important immune organs that can 
secrete key effector molecules like antimicrobial peptides and factors for wound healing 
(Zasloff, 2002).  Many of these responses are released only after immune stimulation via 
damage signal receptors such as Toll (Krautz et al., 2014).  Adipocytes and immune cells 
resident in adipose tissue are also widely recognized to be involved in inflammatory 
processes in higher eukaryotes (Kolodin et al., 2015; Mathis, 2013; Trayhurn and Wood, 
2004).   Anatomically many lymph nodes are surrounded by adipose rich tissue.  Very 
few studies have attempted to understand how the adipocytes around lymph nodes 
respond during immune activation, and this will need to be explored in a variety of 
immune contexts (Pond and Mattacks, 1995). 
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Consistent with previous studies we found that T cells rely on futile cycling of 
fatty acids, a paradoxical process in which cells utilize fatty acid synthesis and fatty acid 
oxidation.  In limiting glucose, T cells increased both fatty acid oxidation and fatty acid 
synthesis.  Energetically this appears to be inefficient, to essentially use ATP and NADPH 
to generate new fatty acids only to break them down again for ATP.  Technically we can 
only measure these processes from large numbers of cells, and thus we don’t know if 
these processes are occurring simultaneously in a single cell.  Previously published work 
determined that during activation IL-15 treated T cells utilized futile cycling more so 
than IL-2 treated T cells (O'Sullivan et al., 2014).  The authors believed that futile cycling 
may be required for long-term survival of memory T cells, and might be extended to 
stem cells and other long-lived cell types.  While the exact reason for futile cycling 
remains largely unknown, researchers have proposed that it may be for generation of 
heat or allow for quicker adaption to regulatory/initiation signals (Curi et al., 2016; Katz 
and Rognstad, 1976).   The role of heat produced by metabolism in T cell activation 
remains unexplored and requires further investigation. 
We also need to examine whether our results on effector memory T cell 
metabolism reflect tumor infiltrating lymphocytes (at least before exhaustion begins) 
and how exhaustion may perturb metabolic adaptation.  In collaboration with Shaun 
O’Brien, Steven Albelda, Jason Standalick, and Sunil Singhal we have received advanced 
stage non-small cell lung cancer patient (NSCLC) samples.  As well described by other 
studies, we found that cells in the adjacent lung and diseased lung tissue are largely 
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effector memory (TEM) or effector memory RA phenotype (TEMRA), losing both CCR7 and 
CD27 expression compared to patient PBMC.  Other studies have observed that tumor 
infiltrating lymphocytes have fewer mitochondria which are smaller and have less 
voltage potential and perform less oxidative phosphorylation (Scharping et al., 2016; 
Siska et al., 2017a).   These defects have largely been confined only to the cells in the 
tumor microenvironment, and not to the T cells in the blood or lymph nodes.  We 
identified that these defects corresponded to all T cells in the lung, both near and far 
away from the tumor microenvironment.  We do not have lung tissue from healthy 
lungs to distinguish whether this might be a lung-specific phenonomena or whether the 
mitochondrial defects observed in the tumor microenvironment apply to the entire lung 
tissue.  However, these data certainly suggest the possibility that tissue-signals, rather 
than tumor-signals act to regulate metabolic signatures of T cells in specific tissues.    
These mitochondrial differences between blood T cells and lung T cells from 
NSCLC patients appear to be highly reversible (data not shown).  We found that 
prolonged in vitro stimulation of NSCLC patient lung TILS and PBMC in vitro removes all 
differences in mitochondrial mass between both populations.   These recent data were 
extremely reminiscent of some of my earliest thesis work, where we sorted T cells based 
on mitochondrial mass.  We isolated CD4 T cells with the highest mitochondrial mass 
and lowest mitochondrial mass.  Upon stimulation, these isolated populations reverted 
back to having an equal mitochondrial mass distribution.  Furthermore, those 
populations did not have observable differences in memory potential or proliferation 
140 
 
following expansion.  This appears in contrast to earlier work where cells sorted on 
mitochondrial voltage potential exhibited differences in memory phenotype upon 
isolation and maintained those differences in differentiation and proliferation during in 
vitro expansion (Sukumar et al., 2016).  These differences in conservation of in vivo 
phenotype during in vitro expansion may simply be because mitochondrial voltage 
potential may act as a surrogate for memory phenotype, whereas mitochondrial mass 
may not.  This work is largely a testament to how much in vivo metabolism information 
may be lost during in vitro expansion.  
Mitochondrial mass may be significantly regulated by tissue location via tissue-
specific signals.  T cells in white adipose tissue have much higher mitochondrial mass 
compared to T cells in the lamina propria (Han et al., 2017).  Interestingly, this 
phenomena was not confined to only resident memory cells but all effector memory T 
cells in the white adipose tissue. These tissue-specific phenotypes may well extend 
beyond mitochondrial mass and extend to entire metabolic programs.  The authors in 
the previous study found white adipose tissue T cells uptake large amounts of 
extracellular lipids in vivo compared to T cells in the spleen or lamina propria.  Skin 
resident memory T cells appear to rely heavily on extracellular lipids for survival and 
persistence (Pan et al., 2017).   Lung resident memory T cells have elevated expression 
of numerous hypoxia inducible factor 1α (HIF1α) and a signature associated with 
glucose depletion (Hombrink et al., 2016) compared to T cells from the blood.  These 
metabolic signatures were linked to the specific transcription factor Notch, which was 
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demonstrated to be vital for survival of lung resident T cells. Identifying tissue-specific 
metabolic signatures for T cells, and the factors that regulate those signatures may be 
critical for enhancing resident memory responses.  What tissue-specific signals regulate 
these metabolic programs in T cells and how permanent are these metabolic programs?  
Furthermore, by identifying the signals driving metabolic signatures in vivo we may be 
able to maintain tissue-specific metabolic programs in vitro.  
Summary, Discussion, and Future Directions for Chapter 4 
 My second major project attempted to identify the activation signals responsible 
for large l structural changes to mitochondria during T cell activation.  Mitochondria can 
swell up to five times their initial size within the first 48 hours of activation, and their 
cristae lose standard shape and patterning.  Despite these sweeping mitochondrial 
changes, we found that T cells were able to upregulate oxidative phosphorylation.  
Cytochrome C is not sequestered inside the mitochondria in T cells activated in optimal 
glucose, and only becomes sequestered when cells are moved into low glucose.  Despite 
observable cytoplasmic cytochrome C, we did not observe caspase activation or cell 
death.  Furthermore using a variety of pharmacological inhibitors and altered 
metabolite concentrations, we observed that mitochondria cristae disruption strongly 
correlated with glycolysis, reactive oxygen species production, and voltage potential but 
not oxidative phosphorylation.   Several studies have indicated that tightly folded cristae 
are required for supercomplex organization which promotes efficient electron transport 
and ATP production (Cogliati et al., 2013; Gomes et al., 2011).  Our data stand in 
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contrast, and strongly indicate that mitochondria can have highly unfolded cristae and 
perform high levels of oxidative phosphorylation.  These data may highlight a novel role 
for Warburg metabolism in modulation of mitochondrial structure and may apply to 
other cell types engaged in aerobic glycolysis. 
 The strong correlation between glycolysis, mitochondrial changes, and ROS 
production suggest a potential model relating T cell activation to mitochondrial changes.  
Our model suggests that glucose drives T cell activation signals such as mTOR, Akt, and 
NF-κB.  Potentially one or several of these intermediate signals directly or indirectly alter 
mitochondrial size and cristae patterning, and we have evidence that at least mTORC1 
activity is required for these mitochondrial changes.  Mitochondrial swelling and cristae 
structure may drive ROS induction and our dta suggest that the two are strongly 
correlated.  ROS production appears to facilitate proliferation in tumor cells and 
subsequent proliferation via IL-2 and NFAT signaling in T cells (Kong and Chandel, 2018; 
Sena et al., 2013).  Thus mitochondria may swell during activation to produce ROS and 
subsequently proliferate.  However, in conditions of sustained mitochondrial swelling 
and cristae disruption, these cells have large increases in ROS production that can not 
only promote proliferation but can begin to induce cell death, which we observe at 
highly increased levels in in hypoxia (data not shown).  T cells in hypoxia have very 
swollen and cristae disturbed mitochondria and high ROS production.  They also actually 
proliferate better than normoxic cells, although this is not reflected by cell number due 
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to increased cell death.  This is our first model derived from largely correlational data, 
and of course as we learn more the order of events in this model may change. 
 The flexibility and rapid adaption of mitochondrial structure to changes in 
nutrient availability revealed by our data is quite striking.  We found that by moving 
activated cells with highly disturbed cristae from optimal glucose to low glucose, the 
mitochondria were able to largely recover patterning and mitochondrial size within 1 
hour.  The speed of these changes likely indicates that they are not regulated by 
transcriptional events.  Traditionally proteins involved in electron transport and 
mitochondria fusion/fission dynamics are thought to regulate cristae shape.  ATP 
synthase dimers are known to be sufficient to induce membrane curvature in lipid 
bilayers (Jiko et al., 2015).  Other proteins like optic atrophy 1 (Opa1), dynamin related 
protein-1 (Drp1), and members of the mitochondrial contact site and cristae-organizing 
system (MICOS) complex also further contribute and cooperate to regulate cristae 
shape.  Several of these proteins like Drp1 are modified post-translationally through 
phosphorylation, which is critical for their activation or inhibition (Marsboom et al., 
2012). While recent work demonstrates that T cells promote mitochondrial fission 
during activation, how all of these regulators work in tandem to control T cell cristae 
during activation remains elusive (Buck et al., 2016).   
 If the mitochondrial permeability transition pore (MPTP) is truly open in 
activated T cells, many proteins and metabolites are potentially leaving and entering the 
mitochondria.  While our initial hypothesis has proposed that these swollen 
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mitochondria promote ROS species to propagate proliferation signals, it is highly 
possible that the migration of mitochondrial proteins into the cytoplasm could further 
contribute to T cell proliferation/function.  Our data suggest cytochrome C is a potential 
protein that leaves the mitochondria, but the possibilities could include many other 
cytoplasmic and mitochondrial proteins or metabolites.  Several laboratories have 
publically presented unpublished data indicating that specific TCA cycle metabolites 
modulate cytokine production.  For example, Luke O’Neill’s group has suggested that 
succinate can control IL-1β production, while citrate controls IFNα production in TLR-
stimulated macrophages. There is a large amount of interest in how these metabolites 
may control epigenetic regulation.  Metabolites can serve as both essential donors or 
cofactors for epigenetic modifying enzymes, and regulate protein activity via post-
translational modifications or post-transcriptional regulation (Minocherhomji et al., 
2012; Pietrocola et al., 2015; Reid et al., 2017; Siska and Rathmell, 2016).  However no 
work to date has focused on how these metabolites leave the mitochondria during 
immune stimulation.  Metabolite transport across the inner mitochondrial membrane 
appears complex and tightly regulated, with the human genome encoding a large 
number of mitochondrial transporters and channels (Kunji, 2004; Passarella et al., 2003; 
Wohlrab, 2009).  Could opening of these channels or pores during T cell activation 
promote an efflux from the mitochondria and facilitate non-metabolic roles for 
mitochondrial metabolites? 
Defining the Next Frontiers of Immunometabolism 
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 It has become clear that the metabolic states of immune cells are fundamental 
to immune function, differentiation, and cellular identity.  Transcription factors critical 
for cellular identity like FOXP3 regulate many cellular processes including metabolism 
(Angelin et al., 2017; Gerriets et al., 2016).  In addition, alterations in metabolism are 
sufficient to induce dramatic changes in cellular functionality, polarization, and 
differentiation.    T regulatory cells typically rely on a careful balance of fatty acid 
oxidation and synthesis, as well as glycolysis for proliferation, migration and suppression 
(Kishore et al., 2017; O'Sullivan and Pearce, 2014; Procaccini et al., 2016).   Excessive 
phosphatidylinositol-3-OH kinase (PI(3)K) activity in T regulatory cells promotes elevated 
glycolysis and as a result these cells lose suppressive activity and have unstable lineage 
commitment (Huynh et al., 2015; Shrestha et al., 2015).  Furthermore, these studies 
demonstrate that while the T regulatory cell population size decreases, a simultaneous 
expansion of the follicular helper T cell population or T helper type 1 cells is observed.   
The links between glycolysis and effector function and fatty acid metabolism with 
suppressive function is continually echoed in the literature in a variety of cell types.  
Immunosuppressive tumor-associated macrophages or alternatively activated 
macrophages utilize higher levels of fatty acid oxidation and oxidative phosphorylation 
compared to more inflammatory macrophages that utilize glycolysis (Galván-Peña and 
O'Neill, 2014; Hao et al., 2018). 
If such a careful balance of different metabolic processes are needed for cell 
identity, how do T cells operate in such a diverse array of tissue environments?  Which 
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metabolic pathways are required in which tissues or inflammatory contexts?  To answer 
these questions, we need to move beyond studying the cells from the blood and spleen.  
Skin resident memory T cells require exogenous fatty acids for survival and protective 
responses during infection with skin vaccinia virus (Pan et al., 2017).  The transcription 
factor Notch is required for maintenance of resident memory T cells in the lung and 
regulates oxidative phosphorylation, glycolysis, and fatty acid synthesis-associated 
genes (Hombrink et al., 2016).  Single tissues have started to be examined, but large-
scale, systematic metabolomic analysis of cells present in different tissues in different 
inflammatory contexts has not been examined.  Recent studies clearly documented that 
immune cells in separate tissues exhibit large phenotypical and metabolic differences 
and are exposed to distinct pathogens over the host’s lifetime (Gosselin et al., 2014; 
Granot et al., 2017; Thome et al., 2014).  Which gene expression differences or tissue-
specific signals drive distinct metabolic phenotypes of cells in different tissues?  
Alternatively, which gene expression differences are due to distinct metabolic 
phenotypes?   
Theoretically it appears dangerous to tie cellular identity and function too tightly 
to metabolism, especially in immune cells that travel to a diverse range of metabolic 
niches.  It appears to limit a cell’s ability to respond appropriately in specific contexts.  
For example, if exposure to exogenous fatty acids promotes a T-regulatory cell gene 
expression profile, what if a strong immune response is needed from T effector cells in 
adipose tissue?  Alternatively, how is the immune system able to function in people 
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consuming high fat or high sugar diets?  How does the immune system adapt to large 
diet changes between people or even overtime within the same person?  A large body 
of work has characterized known immune-associated phenotypes in mice consuming 
different diets.    However, it remains unknown how many of these phenotypes are due 
to changes in nutrient uptake specifically by immune cells. 
 Much of the current work on nutrient availability in immune responses has 
focused on nutrient limitation in the solid tumor microenvironment.  Current work has 
focused on the intense competition for glucose in the tumor microenvironment 
between tumor cells and T cells.  By specifically elevating tumor glycolysis, Ho et al. and 
Chang et al.  have uncovered the critical need for glucose in the solid tumor 
microenvironment for immune-mediated tumor rejection  (Chang et al., 2015b; Ho et 
al., 2015b).  Glucose is not the only key nutrient being competed for between T cells and 
tumor cells, and many other nutrients may be required for anti-tumor responses.  
However studies have not systematically manipulated other specific metabolic 
pathways in tumor cells in vivo to search for additional critical nutrients regulating anti-
tumor responses.  While overexpressing or inhibiting metabolic pathways in tumor cells 
may be useful tools to explore nutrient competition and in vivo relevance of key 
nutrients for tumor responses, we must be careful that our interpretations are not 
caused by alterations to tumor growth independently of immune cells.  For example, 
Chang et al. utilized tumor cells with lentiviral overexpression of various glycolytic 
enzyme in immune deficient Rag -/- mice and found no differences in tumor growth. We 
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also still lack a more holistic view of the competition between the multiple cell 
populations (tumor, effector T cells, T regulatory cells, stromal cells, suppressive 
myeloid populations, etc.) present in the tumor microenvironment.   
Viral, bacterial and parasitic infections can also cause large changes in nutrient 
availability in the serum and tissue (Cui et al., 2018; Eltzschig and Carmeliet, 2011; Zhou 
et al., 2016).  While these changes have been examined, very few studies have sought to 
understand how these nutrient changes during infection can impact subsequent 
immune responses.    In one of these studies, increased acetate availability during 
systemic bacterial infection drove augmented immune function through enhanced 
memory recall responses (Balmer et al., 2016).  Fascinatingly increased T cell activity 
alone is sufficient to decrease serum levels of many amino acids (Miyajima et al., 2017).  
More work is needed to understand how local tissue nutrient gradients promote or 
inhibit immune responses, and which nutrient changes are the most impactful on 
subsequent immune responses in vivo.  Surprisingly little work has sought to understand 
how nutrient availability changes during infections in the lymph node.  During potent 
immune responses, densely packed T cells are rapidly proliferating in the T cell zone, 
swarming around antigen presenting cells and performing large amounts of glycolysis.  
The massive influx and expansion of cells (via trapping of additional naive lymphocytes 
and proliferation of responding T cells) is enough to cause dramatic lymph node swelling 
and stromal remodeling.  Can all responding T cells receive the same amount of glucose 
or other nutrients needed for proliferation and activation?  Are nutrients limiting and do 
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different T cell clones (or even daughters of the same T cell) compete for their 
acquisition of nutrients? Could memory T cells arise from naïve T cells during infection 
because they were unable to acquire sufficient nutrients upon antigen exposure?   
 The utilization of mass spectrometry imaging (MSI, mentioned briefly in Chapter 
3) will likely be a key tool in visualizing nutrient gradients and localization of immune 
cells in situ (Dilillo et al., 2017; Holzlechner et al., 2017). Combined with tissue 
sectioning and technical advancements in improving resolution of MSI, detailed spatial 
organization of nutrient availability and immune cells can be overlaid.  Although nutrient 
gradients and immune cells have been examined separately through MSI, together the 
data can usher in a new understanding of how T cells operate in a variety of contexts.  
This technology has the potential to create detailed maps of nutrient availability and 
how nutrients change during a variety of contexts (infection, cancer, obesity, diabetes) 
and how successful therapeutic or immune interventions alternutrient availabilities.   
 Metabolites play large roles in immune function and differentiation by a diverse 
array of mechanisms.  Mitochondria produced ROS are required for NFAT nuclear 
localization in T cells, adipocyte differentiation through PPARγ, and activation of the 
inflammasome (Sena et al., 2013; Tormos et al., 2011; Zhou et al., 2011).  The glycolytic 
enzyme GAPDH can regulate translation of IFN-γ production, while publically presented 
data by Luke O’Neill’s lab suggests the TCA cycle metabolite, succinate, regulates IL-1β 
production  (Chang et al., 2013).   Acetyl-CoA can donate an acetyl group for histone 
acetyltransferase-dependent acetylation of histones (Wellen et al., 2009).  Thus multiple 
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metabolites can take on a multitude of functions in the cytoplasm, nucleus, or 
mitochondria.  What are the mechanisms by which these metabolites act? And how are 
these metabolites (most notably mitochondrial metabolites) able to travel between 
compartments? Recent evidence indicates that while nuclear and cytoplasmic pools of 
acetyl-CoA are not physically separated because acetyl-CoA can pass through nuclear 
pores, some of the enzymes that generate acetyl CoA can travel to different 
compartments depending on environmental conditions and create local gradients 
(Sivanand et al., 2018).   Thus potentially a cell can temporarily enhance acetyl-CoA 
levels in specific compartments and modify compartment-specific activities.   Both 
global changes and gene-specific changes have been observed by modulating histone 
acetylation through metabolic changes (Lee et al., 2014b; Peng et al., 2016).    
Furthermore while metabolism plays a role in regulating global epigenetic enzyme 
activity, what directs their enzymatic activity to specific genes in the nucleus?   One 
answer may be that acetylation and other post-translational modifications of 
transcription factors can directly regulate their activity at specific loci.  Acetylation is 
well described to modulate the activity of  NF-κB, HIF 1α, Nrf2, and the FOXO family 
(and likely many others) which are known to regulate immunity (Thiagarajan et al., 
2016).   
 We are still discovering new ways in which metabolic pathways influence 
immunity.  Together my thesis offers some new insight into how fuel choice affects 
cytokine production and how T cell activation can influence mitochondrial structure.  By 
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identifying metabolic axes of regulation in immunity, we may be able to create new 
methods to improve existing immunotherapies and vaccines. 
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